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ABSTRACT

Magnetic Resonance Imaging is a noninvasive, complex imaging modality that uses contrast
agents to enhance sensitivity and resolution for a clear image enhancement. To optimize the relaxation
and targeting properties, our lab has created several protein-based contrast agents, ProCAs. To enable
various biophysical characterizations and preclinical studies, we need to optimize expression and
purification of the engineered ProCAs. ProCA1 variants are cultured in various cell strains during a tagless method. ProCA32 with multiple binding sites is also successfully purified. It has a strong metalbinding capability with a relaxivity (r2: 27 ± 0.54; r1: 20.6 ± 0.20 mM-1s-1) that is significantly greater than
the clinically used contrast agent,diethylene triamine pentaacidic acid, DTPA (r1: 3.8 mM-1s-1). Our
findings in optimizing expression and purification conditions, structural conformation, metal binding,
and relaxivity measurements of these ProCAs will facilitate in vitro and in vivo studies needed to move
forward into the pre-clinical then clinical phase.
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1. INTRODUCTION
1.1 Medical Imaging in Cancer Research
Cancer is among the leading causes of death worldwide. It follows that preclinical and clinical
applications are essential for characterizing new drug developments that can be used for the purpose of
cancer treatment, early and effective detection, and accurate prognosis prior to therapy. Mutations
cause uncontrolled proliferation of cell growth to other regions inside the body and result in metastasis.
Essentially, these malignant cells are known as tumors that cause varying forms of cancer.
An accurate determination of the patient’s prognosis is essential for a clinician to make the
decision for treatment options. The patient goes through a specified treatment therapy based on the
progression or stage at which the cancer has developed in the body. Essentially, treatment and diagnosis
rely on the accurate prognosis of the particular disease. Accurately identifying the level of the cancer
helps clinicians have a better diagnosis for treatment and essential suppression of further cancer growth
by continuous therapy [1]. There are several stages of a cancer’s progression. It is essential to locate any
tumors that consist of >~ 109 cells in diameter at the early stage of cancer and are treaTable in the
premalignant stage [1]. The later stages essentially indicate that the cancer has spread to other regions
from the primary tumor site and, at this point, treatment is most challenging. Thus, it is critical to
monitor disease progression at an early stage, and molecular imaging allows this procedure in the
process of cancer prognosis and treatment.
1.1.1 Imaging modalities applied in medical research
In the medical field, various instrumentations are applied for imaging. These various modalities
are used for obtaining anatomical and functional information on the biological process within the body.
There are medical techniques used to indicate and monitor the progression of tumor cell growth. The
essence of cancer diagnosis is the use of imaging applications that obtain a level of sensitivity and
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efficacy for detecting cancerous versus non-cancerous tissue. Some of the most advanced clinical
imaging instruments are positron emission tomography (PET), computed tomography (CT), single
photon emission computed tomography (SPECT), optical imaging, ultrasound, magnetic resonance
spectroscopy, and magnetic resonance imaging (MRI). These modalities are complementary to one
another in the sense that each possesses benefits and limitations to the level of functional and
anatomical information that can be achieved (Table 1.1). They are among some of the techniques
applied for the identification and localization of tumors in order to determine a proper prognosis for
further clinical treatments.
Unlike PET and CT, MRI is a noninvasive medical imaging modality that is not dependent on the
use of ionizing radiation. This application results in a 3 dimensional image of the soft tissue when
exposed to a particular magnetic field strength. Both anatomical and functional information is achieved
with the use of MRI. Each imaging modality holds a different level of sensitivity for detection of tumor
cells. For instance, PET and SPECT have high sensitivity and depth penetration but use irradiation
exposure during image scanning with isotopic labeled agents. Similar to MRI, ultrasound, optical imaging
and MRS are also non-ionizing imaging tools. While ultrasound bio-microscopy is widely used for in vivo
applications, it has limitations for body depth and resolution [2] . MRI provides soft tissue enhancement,
and the important idea is to differentiate the non-cancerous tissue from the cancerous ones in an
effective manner. In this case, the sensitivity is low, so a contrast agent is used to increase the
sensitivity and resolution of the MRI signal.

3

Table 1.1 Comparing the advantages and disadvantages of current imaging techniques [2-5].
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1.2 Principles and Applications in MRI
1.2.1 A brief history on the development of MRI
Magnetic resonance imaging (MRI) was formally known as “nuclear magnetic resonance (NMR)
imaging”. The name was changed to make it less intimating. Jean Baptist Joseph Fourier is among the
key pioneers of contemporary NMR and MRI techniques [6]. MRI operates on the same basic principles
as NMR, the only difference is that a spectrum is obtained for NMR, while MRI outputs a set of 3
dimensional, spatially resolved images [7]. In 1975, Richard Ernst was able to apply Fourier’s famous
mathematical formula and obtain image construction from the MRI [6]. MRI has evolved dramatically
since the initial design in 1980. Scientists Tesla, Lamor, and Rabi paved the way for the use of NMR
imaging, now commonly known as MRI. The clinical MRI field is progressing with new ideas for preclinical and clinical applications [8-10].
1.2.2 Relaxivity Theory
MRI signals are obtained from the water protons, provided by the body,when exposed to a
primary magnetic field (B0) and radiofrequency (rf) pulse. Specifically, the human body constitutes of
~70 % water, or ~90 M of hydrogen atoms provided by these water molecules [11]. MRI depends on the
relaxation of the single proton nuclei for an image signal output. These hydrogen atoms have nuclei with
multiple spin states, which hold a magnetization. During an MRI scan, these nuclei present in the various
tissues inside the body, and will align with the available magnetic field, causing an overall net
magnetization. During this process, the nuclei’s vector is at either spin-up or spin-down direction in
alignment with the magnetic field (B0). The applied radio-frequency pulse then generates a rotational
torque (τr) on the nuclei’s vector. This process then causes precession of the nuclei spin, that is a spiral
motion along the applied rf angle, between the spin up and spin down directions. This process is
dependent on the magnetic field strength (B0), gyromagnetic property of the nuclei (γ), the Lamor
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frequency (ω) and is represented mathematically in Equation 1-1. This initial information gives a clear
understanding on how the MR signal is achieved as an image. The low sensitivity of the MRI results in a
low enhancement between the different tissue contrasts. Thus, a contrast agent (CA) is used to
overcome this image enhancement limitation. The process by which a contrast agent is administered
and relaxes the water’s proton molecules is relaxation rate. The contrast agent in complex form with a
metal ion in solution demonstrates rotational correlation time (τr), longitudinal (r1), and transverse (r2)
relaxation rate characteristics. T1 and T2 relaxation time values each correspond to the reciprocal of the
longitudinal and transverse relaxation rates. Due to the added CA, a better image contrast is observed
for the soft tissues. Each tissue has different levels of water and so they will observe different relaxation
rate and contrast enhancement.

Equation 1-1
Relaxivity is observed when relaxation rate difference is measured as a function of time.
Specifically, this process is the difference in relaxivity demonstrated after the exposure of the CA.
Relaxation time is an important parameter that occurs in two parts: 1) the nuclei spins de-phasing along
the x-y plane is called the spin-spin, or T2 transverse relaxation, 2) the nuclei spin aligning back with the
initial applied magnetic field (B0) along the z-y plane is known as T1 longitudinal relaxation. The main
factors that effect relaxivity are as demonstrated in Figure 1.4 a as a scheme. These factors are as
follow: 1) the water proton exchange dynamic, 2) the contrast agent rotational tumbling rate, 3) the
inner- and outer- sphere water molecules in the surrounding environment, 4) the metal ion and water
oxygen ionic bond distance, 5) the construct and chemical characteristic of the chelating agent. These
factors are all considered and correlate to the criteria for the design approach for our lab’s novel protein
- based MRI contrast agent.
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1.2.3 Characteristics of current contrast agents used for MRI
MRI has a high dependence on contrast agents (CAs) for obtaining clear images. The clinically
approved CA, Gd3+-DTPA (diethylene triamine pentaacetic acid), has a bound lanthanide ion that leads to
increased enhancement of the MRI. The developed contrast agents are specifically designed for Gd3+
binding to form a Gd3+-complex. There is a variety of metal-based CAs used for MRI that has either a
paramagnetic or ferromagnetic property. The paramagnetic-based CAs demonstrates favorable T1weighted imaging, which means that the image enhancement of soft tissue organs (light) compared to
muscle and bone (dark) are brighter after obtaining the MRI scan. Thus, tumor cell localization during
pre-clinical imaging is facilitated based on the light to dark intensity. Iron oxide and nanoparticle (NP)
based agents are examples of ferromagnetic-based CAs developed for use in vivo [12]. T2-weighted iron
NPs demonstrate the opposite enhancement effect on an MRI scan that is less desired for medical
imaging, and the iron nanoparticle agents pose a challenge for maintaining stability during synthesis
[13].
The lanthanide compounds, specifically gadolinium (Gd3+), are important for obtaining a
reasonably high relaxation rate. The focus of this study addresses gadolinium-based contrast agents.
Rotational correlation time (τrot) and relaxation rates are two important components that contribute to a
clear MRI. In addition, these parameters are directly proportional. Free Gd3+ are highly toxic to the body.
1.2.4 The toxicity level and nephrogenic systemic fibrosis relationship with GBCAs
Nephrogenic systemic fibrosis (NSF) is a disease caused by the exposure of high levels of free
metal ion in the body. Specifically, a study has followed up on the claim that this disease is mainly
present in patients who suffer from chronic kidney disease or kidney failure. These specific patients are
more prone to develop the symptoms associated with this disease. A symptom involves the
discoloration of skin and organs in the body such as heart, lungs, and the central nervous system. Some
studies associated the development of the disease and patients with renal failure that are administered
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a dosage of small GBCA. The link between NSF development and GBCAs dosage brought an emphasis on
safety by the FDA. The patients who suffer from kidney failure are administered other type of CAs or a
lower dosage then the clinically used dosage for obtaining an MRI scan. Other precaution in which the
FDA has developed is in regulating the pharmacokinetics and bio-distribution of the Gd-based contrast
agents. Once administered in vivo. This same study also indicates that from a large group of test
subjects, the results were inconclusive in terms of supporting the initial claim that renal impaired
patients are prone to develop NSF due to the administration of GBCAs. Thus, the correlation between
the dosage amount of GBCAs and patients with kidney failure are on a going surveillance since the initial
outbreak cases in 2001.
Specifically, GBCAs are composed of a small organic compound bound to gadolinium ion. The CA
provides a clear difference in the image contrast due to an increase relaxation rate. Gd3+ ions interact
with the water molecules present in the surrounding soft tissue, and this interaction gives off a
relaxation rate in the form of image enhancement. However, Gd3+-DTPA and other small chelator based
MRI contrast agents shown in Fig 1.2 have a relatively low relaxation time (r1: 3.8 mM-1s-1) due to their
small molecular size. The molecular imaging contrast agent database (MICAD) lists twelve different
derivative based agents used for MRI [14]. Thus, our lab has designed a protein based contrast agent,
(ProCA), which possesses a higher relaxation rate compared to the CAs currently in use clinically.
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Figure 1.1 A timeline history leading to the establishment of clinical MRI applications [6].
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Figure 1.2 Variations of the clinically used gadolinium-based contrast agents (GBCAs) for MRI
application system [15].
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Figure 1.3 The relaxivity process of excited proton nuclei during MRI scans.
The two proton nuclei relaxation processes are b) T1 longitudinal relaxation time and T2 transverse
relaxation time occur after a) an applied radiofrequency in presence of a magnetic field [7, 16][17]. b)
The vector of the proton nuclei de-phase out of the lattice or surrounding along the x-y plane as a
function of time. This process is T2 spin-spin relaxation (purple). The proton nuclei rotate along the z y plane in the lattice then gradually re-align with the applied magnetic field (B0) along the z - axis
(green). This process is known as spin-lattice relaxation. Both relaxation processes are important to
understand the physics of how an MRI signal is transmitted as an enhanced image. The contrast agent
acts as a catalysis to slow down the tumbling rate of the water protons once it is administered into
the patient‘s body. This process causes the relaxation rate to increase and a more distinct image
contrast between the various types of soft tissues and organs are enhanced.
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1.3 Development of the Novel Protein-Based Contrast Agents (ProCAs) for MRI
The limitation of the MRI technique is the use of a CA as previously mentioned. Specifically, the
CAs provided has to fulfill certain requirements such as: low toxicity, high permeability, strong targeting
capability, low dosage, and high relaxivity for efficient analysis of the image enhancement. In
considering these characteristics, our lab has developed novel designed protein based contrast agents
for MRI applications. Furthermore, these novel ProCAs are divided into various generations but only
generation one and three are discussed in this study. ProCA1 and ProCA3 are generated from different
protein scaffold. Each of the scaffold proteins have unique characteristic in terms of sustaining
conformational stability prior to multiple site mutagenesis.
1.3.1 Criteria to consider prior to applying the design approach for protein-based Contrast
agents
Relaxation process is dependent on many factors. The involvement of each of these factors is
illustrated in Figure 1.4 and they are noted as essential criteria. The criteria to optimizing the image
enhancement properties of the novel designed contrast agent involve the following: 1) high relaxation
rate, 2) strong metal binding to reduce toxicity associated with nephrogenic systemic fibrosis (NSF), 3)
low immunogenicity, 4) enhanced detection of tumor cells and tissues, 7) good pharmacokinetics in vivo.
Water number value is an important parameter when studying relaxation measurement.
1.3.2 Model for the contrast agent: Background on the scaffold protein
CD2.D1 originates from the T- cell receptor in the immunoglobulin response system [18]. This
protein maintains conformational stability at varying pH and salt concentrations, which indicates a high
tolerance to mutation. Previous studies on the use of rat CD2.D1 as a model for designing calcium
binding protein confirm this conformational stability towards mutations [19]. It has two tryptophan
residues, one buried in the hydrophobic core at position 32 and one exposed in the hydrophilic surface
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at position 7 (Figure 1.4 b). This protein consists of a β-sheet topology with an immunoglobulin
superfamily (IgSF) domain [18]. It poses no complications in terms of folding due to no cysteine residues
present in the loops.
1.3.3 Design approach for the novel ProCA1 variants
ProCA1 derives from a metal binding pocket inserted on the surface of the first domain of the
rat cell cluster of differentiation 2 (rCD2.D1). Figure 1.5 b summarizes the following four engineered
protein binding sites: CD2.7E15, CD2.7E15E, CD2.7E15N, and CD2.7E15Q. The following terms referring
back to the mutations will be used throughout this thesis: 7E15, 7E15E, 7E15N, and 7E15Q. These
mutations are designed by a former research colleague, Dr. Anna W. Mannicia, with the intention of
analyzing the effect of charge numbers and ligand types at the metal binding pocket on protein folding,
stability and metal binding affinity [20]. 7E15 has mutations at positions 15, 58, and 64. The designed
ProCAs are T1-weighted MRI agents due to the high positive contrast enhancement during T1
longitudinal proton relaxivity measurement. Thus, the engineered binding pocket has a pentagonal bipyramidal coordination confirmation with Gd3+ (Figure 1.5 a). In addition, the net charge of the binding
site is indicated for CD2.7E15 (-5), CD2.7E15E (-5), CD2.7E15N (-4), and CD2.7E15Q (-4) (Figure 1.5 b).
The binding affinity of a metal- protein complex determines the strength of the residue side chains
interaction with the ion [21]. The original aspartic acid residue is mutated to glutamic acid, named
7E15E, following aspartate (7E15N) and glutamate (7E15Q). 7E15 and 7E15E hold a - 5 charge while
7E15N and 7E15Q have a - 4 charge. The different charge of the binding pocket is essential for
comparing the binding affinity to the metal ions during fluorescence titration and relaxation rate
measurement. The binding pocket coordination geometry is described as a pentagonal bipyramidal for
the Gd3+ ion complex with the five-ligand side chains. It is assumed that this coordination is sTable but
theoretically decreases in affinity depending on the metal ion atomic radii present. For instance,
lanthanide metals Ln3+ (1.94 Å) and Tb3+ (1.81 Å) have similar atomic covalent radius to Gd3+ (1.84 Å),
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while zinc (1.2 Å) has a lower atomic covalent radius but higher electronegativity. The other
physiological metals such as Ca2+, Mg2+, and K2+ have similar atomic radii as well in comparison to Gd3+.
These ionic radii comparisons help in obtaining an understanding on the binding affinity or dissociation
constant (Kd) value obtained for each protein variants during fluorescence titration. These metal binding
studies are discussed in detail in the results and discussion of Chapter 4.
We must optimize expression and purification methods to increase production yield and further
continue the study with a detailed biophysical analysis (e.g. metal binding affinity, relaxivity
measurement) on the purified ProCA samples. ProCAs are expressed and purified for further
conformational analysis. The expression behavior of the mutants is analyzed in this study when
expressed in varying E. Coli cell strains. The sole purpose is to obtain an optimized condition for
expression and purification of ProCAs as efficiently as possible, so they can be used for further analysis
in detecting cancer cell markers such as HER2 when injected into mice for pre-clinical trials [22] .
Abada et al. demonstrated that a macro cyclic gadolinium-based contrast agent with phosphate
ligands has a two-fold higher relaxivity (r1: 8.5 mM-1s-1) compared to the CA with carboxylate ligands (r1:
4.2 mM-1s-1) [23]. Such results give rise to questions involving whether change in ligand may have an
effect on the relaxation rate properties of the contrast agents. For our initial design approach of the
binding pocket, the ligands are the side chains of three aspartic acids and two glutamic acids, which
make a - 5 charge on the beta sheet surface (i.e. B, D, E) of what is known as CD2.7E15 or ProCA1
(Figure 1.4 b). It is also very interesting to see the effect of electrostatic interactions or different ligand
residues on these properties of designed protein contrast agents. Table 1.2 lists each created variant
that is related to this study and their corresponding design rationale.
1.3.4 The Grafting approach for promotion of the ProCA1 targeting capability
Human epidermal growth factor receptor (EGFR) and type 2 (HER2/neu, ErbB2) are defined as
biomarkers commonly found and expressed on various cancerous cells, specifically breast and ovarian
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cancer [24-26]. Our lab has established a targeted contrast agent by engineering an affibody protein
domain (~7.5 KDa, 3 helices) for targeting the tumor receptors (Figure 1.7 d) [22]. Affibody is utilized as a
probe for image diagnostic and therapy, and mimics antibody-targeting capability, but they are derived
from a phage display library from the Z domain of staphylococcal protein A (SPA) [27]. Two varying
mutants are analyzed in this study. HER2 targeted contrast agent called ProCA1.affiZHER342 and EGFR
targeted contrast agents called ProCA1.affiZEGFR1907 (Table 1.2). A lab colleague, Dr. Jingjuan Qiao
grafted these affibody-targeting peptides to the c-terminal of ProCA1. A five-residue linker joins the two
moieties. The GGSGG linker is chosen because it allows sufficient movement and prevention of steric
hindrance between the two moieties. These developed targeted protein contrast agents have improved
the sensitivity and specificity compared to the conventional FDA-approved/clinically-applied CAs such as
Gd-DTPA. The various in vivo studies demonstrate the successful increase in relaxivity and image
enhancement, as well as endothelial penetration and even bio distribution of the ProCAs [16, 22, 28-29].
In contrast, other derived targeted bio-based contrast agents such as antibody, micelles, nanoparticles,
iron oxide, do not demonstrate such even bio distribution capability due to their size. In Chapter 4 of
this thesis, I will report our effort to improve expression and purification of these variants and
biophysical characterization of these variants that are important for future in vivo applications.
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Figure 1.4 Schematic representation of the factors that affect a contrast agent’s relaxation properties.
a) The various water protons present in the surrounding environment interact with the gadolinium ion
during administration of the gadolinium-based contrast agent. B) ProCA demonstrating a spin lattice
relaxation rate at a higher range than Clinical CAs during the increased field strength (MHz). c) The
various pegylation with lysine residues on ProCA1 surface promotes low immunogenicity and
increased permeability and half-life in the blood vessels. Figures referenced from [29].
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Figure 1.5 The alignment of the ribbon surface between human and rat derived CD2.D1.
The alignment of the ribbon cartoon of a) hCD2d1 (purple, generated from Pymol through pdb code:
1HNF) and b) rat CD2.D1 (blue, generated from Pymol through pdb code: 1HNG). Trp 7 and Trp 32 are
highlighted yellow [30]. c) ProCA1 has a binding pocket designed specifically for forming a complex
with gadolinium cation. d) The clustal protein sequence alignment for human/rat CD2 and CD2.7E15
indicates the conserved residues maintained from both species [31].
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Figure 1.6 The binding pocket for the single site mutation of ProCA1 variants.
The listed variant has it's a) corresponding charge, residue labeled, and is generated using PyMOL
software [30]. b) The Table summarizes the cartoon representation of the enlarged binding pocket
region with its five residues compared to the wild type parent protein (CD2.D1).

18

Figure 1.7 The different factors involved when using affibody as a multimodal probe for MRI scan.
The overall scheme of a) the signal transduction pathway that are mediated by different tyrosine
kinase receptors. b) Specific heterodimer formation between the EGFR and HER family and the
binding of the targeted drug (Ertotinib) for the down regulation of cancer cell proliferation. c) The in
vivo targeting capability of cancer xenograft mice models with the HER2 binding site cartoon on alpha
1 and alpha 2 helices (generated by PyMoL, PDB code: 2KZI) [30]. The designed model of
ProCA1.affi342-m pegylated with PEG40 for an improved multimodal probe [26, 32-33].
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1.4 Amount of Protein Needed After Optimizing Protein Expression and Purification
The novel engineered protein-based contrast agents (ProCAs) are established for MRI usage. The
production of these ProCAs is in need for a progressive analysis of these proteins in vivo. It typically
takes 10 to 14 years for a newly developed drug to pass through clearance for use at the clinical phase
[3]. The basic steps to taking a drug into the clinical phase involve rigorous preliminary studies. These
studies refer to the large scale-up production of these engineered ProCAs. The expression and
purification conditions are the main focus for the production parameters. These methods are crucial for
establishing an optimal protocol that can transition into the industry for the production of the novel
ProCAs. Clinical imaging is the long-term goal and it entails using ~ 0.10 mmol/kg subject weight of 0.5
M solution dosage for human MRI imaging depending on the contrast agent and the subject’s weight.
Prior to transitioning into the pre-clinical then clinical phase, the ProCAs are expressed then purified
based on the selected methods mentioned in Chapter 2 and Chapter 3. Table 1.2 summarizes the typical
protein amount needed for each biophysical application. The main instruments that are applied in this
thesis are fluorescence emission spectroscopy, circular dichroism, and relaxometer. The total protein
weight is indicated at the milligram amount for the specific biophysical techniques used for the analysis
of the function and structure conformation of the purified ProCAs. This indicates that a microgram to
milligram amount of these ProCA1 variants are crucial for continuous structural and functional
characteristics, and relaxation measurements for in vitro and in vivo applications (Chapter 4).
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Table 1.2 Summary of the amount of protein needed for each biophysical analysis.
The results (Chapter 4) are obtained based on these highlighted biophysical techniques (orange).
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1.5 Overall Purpose of this Study
1.5.1 Production of these novel protein-based MRI Contrast Agents
The expression and purification conditions are altered and the results are analyzed. The result
that is best suiTable for progress at the large industrial scale can be devised based upon the trouble
shooting of parameters during expression and purification. The optimized conditions for purification are
analyzed for best bioactivity, protein stability, low toxicity and low contaminants. Basically, each
conditions changed during purification are screened for better results. Specifically, the best results that
are suiTable for this study involve achieving low contaminants, high yield, and sTable functional ProCAs
at a low cost and less time consuming manner. Comparing the tag-less and glutathione-S transferase
(GST)-tag purification systems are amongst the main direction to which we can determine what
purification system will satisfy for the efficient and high quality production of these novel based
engineered ProCAs. This study only focuses on expression and purification of the rat CD2.D1 scaffold
protein. Eventually, human-derived CD2.D1 variants will be analyzed and the established optimized
conditions can be applied to those variants as future work. A standard optimal expression and
purification method that follows a current good manufacturing practice (cGMP)-like procedure must be
obtained as well. In addition, we must be able to transition into an industrial large-scale method for
application in vivo, specifically large animal experiments (i.e. rats, dogs, monkeys).
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Figure 1.8 A scheme of the overall goal in this thesis study.
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1.6 Overview of this Thesis
In this thesis, the production of the previously designed and engineered variants of ProCA1 from
Dr. Anna W. Maniccia and Dr. Jingjuan Qiao’ s dissertation, and ProCA32 variant from Dr. Shenghui Xue’s
dissertation are discussed in detail in Chapters 2-5. Specifically, the objective of Chapters 2 and 3 is to
seek optimal conditions through: change in parameters during expression and purification methods for
obtaining high yield, low toxicity, high purity, sTable bioactivity of protein of interest through an
effective, low cost procedure. This applies as well to all other ProCAs that will be mentioned throughout
this study. In Table 1.3, each charged variant tackled in this study is summarized with its associated
mutation, purpose for the mutation, and related Chapters.
In Chapter 2 of this thesis, expression conditions for tag-less ProCA1 charged variants are
analyzed by change in host cell strain. Competent cell strains used are BL21 (DE3), BL21 (DE3) pLysS,
Tuner, and Rosetta-gami (DE3) pLysS. Henceforth, these cell strains are named BL21, BL21 (DE3) pLysS,
Tuner, and Rosetta-gami pLysS throughout Chapter 2 and 3.

The tag-less expression method

demonstrates low molecular weight at ~ 11.2 KDa for each ProCA1 charged variants, which are listed
below in Table 1.2. Chapter 2 describes the effect of recombinant protein production is dependent on
the used host cell strain. Each cell strain has a deletion mutation, which gives them a specified
characteristic during expression system. For instance, ProCA1 charged variants expressed in BL21 (DE3)
pLysS cell strain demonstrate lower production at higher molecular weight compared to BL21 and
Tuner. Tuner is dependent upon the concentration of inducer added during the expression and this
phenomenon is demonstrated from the expression gels and final yield post FPLC-Q column isolation
(Section 2.3 of Chapter 2). Further isolation of the concentrated pure samples is passed through a size
exclusion high-pressure column but the yield is decreased dramatically.
The expression and purification conditions of GST-tag charged ProCA1 charged variants and
targeted ProCA1.affibody variants are tackled in Chapter 3 of this study. The following parameters for
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expression system are analyzed: a) the temperature post induction, b) the inducer (IPTG) concentration,
and c) the host E.coli cell strain. The following parameters for the GST-tag purification system are
analyzed: a) 100 mg lysozyme/per 1 L culture, b) use larger diameter column, c) use 10 mM DTT and
0.05 % triton X-100, and d) use of a refolding method on inclusion body GST-tag ProCA1 charged
variants and ProCA1.affibody variants. Summarized expression and purification data for GST-tag ProCA1
charged variants through change in conditions/parameters are listed under Section 3.3 of Chapter 3. The
yield from each host cell strain and purification conditions for all variants charged and targeted is
summarized in Section 3.3.
In addition to obtaining an optimal condition for expression and purification, the structural and
functional characteristics are summarized in Chapter 4. The secondary and tertiary structural
conformation stability of the ProCAs is tested through monitoring the secondary structure with circular
dichroism and tertiary hydrophobic folding with tryptophan-fluorescence emission spectroscopy. The
functional characteristics involve determining the metal-binding affinity of the binding pocket to the
lanthanide metals Gd3+ and Tb3+. The metal binding study for Tb3+ is observed through the following two
fluorescence methods: a) a buffer system titration method, and b) a competition assay using FLuo-5N
dye. The summarized Kd for each of the titration methods for ProCA1 variants targeted and charged are
compared in a Table that is available in Section 4.3 of Chapter 4. The competition method is applied for
Gd3+ binding affinity determination with the use of a Fluo-5N Invitrogen commercial dye. Furthermore,
the relaxation properties are measured with change in ProCA1 variants to Gd3+ concentration ratio, and
analysis of relaxation rate change in relation to ProCA1 variants concentration change with the fixed
Gd3+ concentration. The ProCA32 variant has a different scaffold protein and two binding pockets
compared to ProCA1 variants mentioned previously.
The conventional bench work purification system of the fed batch fermentation for ProCA32 is
analyzed and compared to two other systems. Specifically, the conventionally expressed ProCA32 and
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fed-batch fermented ProCA32 pellets are compared through the typical bench work purification system.
In addition, the ProCA32 pellet from fed-batch fermentation is purified through the use of a specified
PEG concentration. Essentially, all three tactics for purification are compared in terms of overall yield
after FPLC-Q column isolation. The relaxation properties at varying ratio of the ProCA32 to Gd3+
concentration are also compared for each sample obtained from the individual expression/purification
systems. The purified ProCA32 from fed-batch fermentation is analyzed for structural and functional
stability through an NTA-buffer system titration and a competition assay with FLuo5N titration using
Fluorescence spectroscopy. Chapter 6 describes the goals achieved; the challenges, and the major
findings from this study overall.
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Table 1.3 The summary of ProCA variants used in this study [20, 29, 34-36].
All ProCAs of the rat scaffold protein CD2.D1. All ProCA1 charged variants are referred as: ProCA1, 7E15E, 7E15N, and 7E15Q for the design
approach in the binding pocket. The grafting approach at the c-terminus of ProCA1 is represented based on ProCA1.affi342 targeted towards
HER2/neu and ProCA1.affi1097 targeted towards EGFR cancer biomarkers. The derived ProCA32 represents the 3rd generation of designed
protein based contrast agents and holds two binding pocket compared to the first generation ProCA1 that has one binding pocket design on its
scaffold’s surface.
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2. EXPRESSION AND REFOLDING PURIFICATION OF TAG-LESS PROCA1 VARIANTS IN VARIOUS E.
COLI CELL STRAINS
2.1 Introduction
The general factors involved in the production of our recombinant ProCA1 variants are: 1)
plasmid/vectors, 2) competent host cell strain, and 3) cultured media for the expression system, 4)
method for the extraction of protein, 5) collecting the soluble (supernatant)/insoluble (inclusion body)
form for the desired purification system. The correlation between each of these criteria is summarized
through a scheme in Figure 2.1. The chosen vector depends in part on the planned purification
technique, such as pET with 6-Histidine tag (His-tag), or pGEX system (GST-tag), or pMAL for maltose
binding protein tag, all involving a tag purification method for efficient protein yield. My focus in this
Chapter is specifically directed at the tag-less expression and denaturing - refolding purification methods
of the ProCA1 charged variants, while the fusion-tag system is discussed later (Chapter 3) as a
comparison.
The parameter in the expression procedure tested for optimal cultivation results is the change in
the host cell strain for tag-less ProCA1 charged variants. Specifically, 7E15E, 7E15N, and 7E15Q are
expressed and purified, followed by the calculated yield (mg/L). E.coli is a commonly used bacterial host
cell strain, and there are many commercially available competent cells derived from E.coli. The use of
the bacterial cell strains gives a high throughput of the protein of interest (ProCAs) in a short time limit.
The host E.coli cell strain is the production machinery used for expressing the protein of interest. The
complex mechanism taken place inside the E.coli cell depends on several factors that indirectly play a
role during the over-expression of our recombinant protein. Some of these factors involved in the
expression system are: the inducer concentration, temperature set after induction, and the host cell
strain. The host cell strain is the condition I draw my focus when analyzing for the best optimal
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expression level of tag-less ProCA1 variants.
The four cell strains are as follows: BL21 (DE3), BL21 (DE3) pLysS, Tuner, and Rosetta-gami (DE3)
pLysS are examined in the LB broth medium. Table 2.2 summarizes the specific mutation and
characteristic of each of these listed cell strains. Based on Natalie White’s thesis, Tuner cell strain
promotes high inclusion body yield of the protein of interest, which is compatible for the refolding
purification method [34]. BL21 (DE3) is the host cell that allows for the expression of plasmids containing
a T7 promoter site. The same cell strain with the added pLysS mutation activates the T7 lysozyme, which
allows for low basal expression of the protein prior to induction. This particular host cell also prevents
the high expression of toxic proteins to allow for successful translation of the protein to occur once cells
are induced in the luria-broth media. Rosetta-gami pLysS holds a similar characteristic to BL21 (DE3)
pLysS, but in addition it allows for promotion of rare tRNAs for translation of rare codons (i.e. AGG, AGA,
Arg, AUA Ile, CUA Leu, CCC Pro, GGA Gly) [37]. I utilized this information and tested if there is a
correlation between the expression level of the protein and the yield of the protein after the purification
process. The expression conditions that give a higher ratio of the protein in the inclusion body is most
suiTable for the tag-less refolding purification system.
There are multiple large-scale expression and purification systems that are used for the
production of potential agents to be used in medical applications [38]. For instance, Cox et al. devised a
more effective three step purification method for recA genome of E.coli, which plays a vital role in DNA
replication, annealing and regulation of DNA mutation/repair where the purification system only
involves three steps: 1) lysing the cell in specified buffer, 2) collecting /solubilizing pellets, and 3)
isolation through a series of chromatographic steps (i.e. phosphocellulose and single stranded DNA
cellulose) that involve no gradient buffer elution [39]. The purification approach that I focused on is in
the refolding of the designed ProCA1 variants that are cultured with a pET20b vector. Through a set of
trial and error, previous lab members have established the current refolding protocol for these ProCA1
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variants that are mainly found in the inclusion body after cell lysis [34].
The focus of this Chapter is on the tag-less expression and refolding purification methods. The
tag-less purification method involves recovering the misfolded ProCA1s through a refolding system. The
pellets are treated with harsh denaturant at a high concentration for optimal unfolding of the ProCA1s.
The protein’s tertiary confirmation is recovered through a step-wise dialysis and dilution process. There
are current studies that focus on similar refolding purification protocols [40-45]. The advantages and
challenges when utilizing the refolding purification system are compared in Table 2.3. One drawback
from applying this purification procedure is possible presence of nucleotide contaminants and
aggregation during the refolding process. Although a high concentration and yield of the protein can be
recovered through the denaturation-refolding system, aggregation still poses a problem when refolding
the protein back to its native tertiary structure. Another challenge facing the denaturing-refolding
purification method is the recovery of the protein‘s native functionality as a chelating agent. Solving the
drawbacks during the recovery of the protein from the inclusion body is crucial for effective production
and reproducible protein yield. So we raise the question: How can we promote the increase in the
production of these ProCA1s variants and move forward with the refolding purification? These
challenges involved in the refolding purification system can be overcome through troubleshooting of
important parameters as demonstrated by current studies. Essentially, our attention is the expression
system level and how it affects the purification system in terms of protein yield (mg/L).
Theoretically, the low expression level of the recombinant protein can give low yield after
purification. We want to determine which cell strain gives the highest ProCA1 charged variants yield
(mg/L), lowest contamination for DNA/nucleotides, and the solubility level of each ProCA1 charged
variants during cell lysis prior to the denatured-refolded purification system. Our effort is directed at
analyzing the expression level of our ProCA1 variants during cultivation and then proceeds through the
effective recovery of its tertiary structural conformation after the refolding purification method. The
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overall work in this Chapter consists of the following: a) the small-scale expression of ProCA1 in two
different cell strains, b) the large-scale expression of 7E15E, 7E15N, and 7E15Q in varying E.coli cell
strains, c) the refolding purification method applied to the large scale expressed variants, and d) The UVVisible absorbance spectrum and final yield in milligrams from each cell strain expression system.

Figure 2.1 The general factors to consider for the expression and purification systems[46-47].
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Table 2.1 A summary of the properties for the four E.Coli cell strains [37, 48-51]

Table 2.2 Comparing the advantages and challenges for the refolding purification method [40-43, 5253].
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2.2 Methods
2.2.1 Cloning
The charged ProCA1 variants (from Chapter 2 to 4) cloning are described according to the
protocol in Dr. Anna Wilkin’s dissertation [20]. The targeted ProCA1 variants to HER2 peptide (from
Chapter 3 to 4) cloning are described according to the protocol in Dr. Jingjuan Qiao’s dissertation [36].
2.2.2 Transformation
To begin this method, the following E. Coli cell strains: (BL21 (DE3), Rosetta-gami (DE3) (DE3)
pLysS, BL21 (DE3) pLysS, and/or Tuner, were allowed to thaw in an ice bucket. The CD2.7E15 (or ProCA1)
DNA plasmid with a pET-20b (for Chapter 2) or pGEX-2T (for Chapter 3) vector was also thawed in the ice
bucket. The competent cell (50 µL) was then mixed with the DNA plasmid (0.50 µL) in an empty
autoclaved eppendorf tube, and then left on ice for thirty minutes. In following, a water bath at 42 ºC
was controlled. The eppendorf tube containing the mixture was transferred into the water bath for 90
seconds, and then quickly transferred back on ice for two minutes. This crucial heat shock method
possessed an impact on the cell strain’s membrane wall. The cell membrane was vulnerable in this step
and as a result the foreign DNA plasmid that holds the recombinant DNA sequence of the protein of
interest was present in the cytoplasm of the competent host cell. Prepared autoclaved LB Broth Miller
medium (75 µL) was added to the cell/DNA mixture and placed in the Isotemp incubator (Fisher
Scientific) for 30 minutes at 37 ºC. After obtaining the incubated tube, the mixed solution (50 µL) was
placed in the center of the luria-broth agar with ampicillin antibiotic plate and spread with the use of a
sterile triangle. The plate was then placed for incubation at 37 ºC for overnight. The next morning the
plate was observed for any colony growth and placed in the 4 ºC refrigerator with parafilm.
Transformation methods is summarized as a scheme in Figure 2.2 for all expressed 7E15 and charged
variants. Note: all proteins expressed in this Chapter 2 involved the Tag-less vector pET-20b.

33

2.2.3 Small and large-scale expression
Inoculation was the first step in the expression methods for CD2.7E15 wild type. This step was
quick and the flask (1000mL capacity) was placed in the shaker (Branstead Lab-line, ~200 rpm,
temperature 37 ºC, Max Q 5000), which was used to spread the nutrients and oxygen within the
available space in the flask for overnight (o/n). The second step involved the transfer of the overnight
culture into the two larger one Liter Luria-Bertani media flasks (2800 mL capacity) for the large-scale
system while a 10 mL volume of fresh media is used in sterile plastic falcon tubes (50 mL capacity) for
the small-scale system. The O.D. readings were recorded with the use of a UV-Vis spectrophotometer
(UV-1601, Shimadzu Scientific Instruments Inc., Columbia, MD) at a fixed wavelength (λ = 600 nm). The
bacteria cell pellets were collected on the same day after induction for four hours through the use of a
low speed centrifuge (Sorvall Model RC5Bplus, MFD by Kendro Laboratory products, Newton, CT). The
collected cell pellets are then placed in the - 20 ºC freezer until further application for the purification
process. All charged variant proteins are expressed in large one liter flasks left overnight at 30 ºC in
following the collection of the proteins the next morning. Expression of charged variants in BL21 (DE3)
involved inoculation o/n at 37 ºC in sterile plastic based falcon tubes (50 mL capacity).
2.2.4 Tag-less refolding method
Re-suspending the cell pellet from the expression methods in a prepared lysis buffer was the
initial step to the denaturing-refolding purification methods for 7E15 and it’s charged variants. The
sonication step soon followed and it was repeated five to six times for 30 seconds with a five-minute
interval with cooling on ice. The bacteria cells were treated with a constant vibrational force, which lyses
the cell wall and exposed the protein of interest to an unsTable environment. Thus, it was important to
keep the solution under ice as the sample overheats during the protein extraction process from the host
cell. The solution is then centrifuged at high speed (17 Krpm, Sorvall RC-5B Refrigerated Superspeed
Centrifuge, Du Pont Instrument, Newton,CT) for 30 minutes. The cell pellets are washed with 2 % Triton
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x-100. In following the protein in the pellet are denatured by prepared 8 M urea (OMnipur min 99.5 %,
EMD Chemicals Inc. Gibbstown, NJ) o/n. The next morning the protein is centrifuged and supernatant
(SN) is transferred into dialysis bags. The protein refolding process is executed with treatment of 2 M
Urea then 10 mM Tris buffer placed inside a 2000 mL plastic beaker for overnight. The solutions are
collected and stored in sterile falcon tubes at -20 ºC until the next purification process (Fig 2.3).
2.2.5 FPLC- anion exchange Q – column
Fast Protein Liquid Chromatography (FPLC, General Electric, #INV-907, made in Sweden) is a
chromatographic process in which the protein in solution is exposed to a salt gradient (Q-column)
program (Figure 2.5). The program system was initially washed with ultra pure deionized water (ddH2O).
The 10 mM HEPES (Free acid, molecular biology grade, 99.7% purity, EMD Biosciences, Inc. LaJolla, CA)
buffer (pH ≈ 8.0) and 10 mM HEPES, 1M NaCl (Crystals, GR ACS, EMD Chemicals Inc. Gibbstown, NJ)
buffer (pH ≈ 8.1) are prepared and used as Buffer A and Buffer B, respectively. The column is gradually
washed with the salt buffer so protein is eluted out of the column as the percent salt concentration
increases gradually as demonstrated in the results (Figure 2.9 and 2.10).
2.2.6 Quantitative analysis of the 15 % SDS-PAGE through Image J software
Since the majority of the expression and purification results were mainly qualitative, we utilized
Image J software (1.47v, Rasband, Wayne, NIH, USA) to quantitatively measure the protein’s band
intensity. Essentially, the intensity of the band was measured and this value was used for the analysis of
the small and large-scale expression results. The gel results for the expression (2.3.1 and 3.3.1) and
purification (3.3.2) were quantified through a normalized intensity ratio value. The bands that
demonstrated the low intensity ratio represented a low expression in correspondence to the dark pixels
of the imaged SDS-PAGE.
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2.2.7 Ultraviolet-visible absorbance spectra and agarose gel electrophoresis applications
Analytically, the purified protein solutions were analyzed for the contents of DNA contamination
through a UV-VIS spectrum generated on the computer (UV- probe version 2, Pharma spec. 1700,
Shimadzu scientific Instrumentation Inc. Newton,CT).In addition, agarose gel was used to indicate any
presence of DNA in the protein solution ( 6 µL of SyBr indicator, 10 µL of HiLo marker, 10 µL prepared
supercoiled DNA marker, at 80 volts) . Quantitatively, the UV-VIS absorbances were recorded for each
concentrated protein solution, in order to determine the final protein concentration (CF) experimentally.
Nanopure water (ddH2O) (800 μL) was added to the quartz cells. The baseline was run initially prior to
adding the protein sample in the cell. In following, auto zero was used on the absorbance value prior to
adding a desired amount of the concentrated protein into the cell in the sample holder position. Shortly
after the display of the spectrum, the absorbance maximum value at 280 nm was multiplied by the
dilution factor in order to obtain CF with Equation 2-1. The theoretical molar absorptivity (13940 M-1cm1

) was determined through a protein web calculator database while the experimental molar absorptivity

was determined in our lab 11700 M-1cm-1 [54]. The experimental molar absorptivity value was used in
the Beer Lambert Equation for obtaining CF.

Equation 2-1

Note: All samples collected during expression and purification methods were run through 15%
SDS-PAGE and recorded as data.
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Figure 2.2 The transformation scheme along side the pET-20b vector containing the T7 promoter site.
IPTG is an inducer that activates the T7 promoter site located in a) pET20b (+) vector [55], which promotes the overexpression of the
recombinant DNA fragment of ProCAs during the induction process. b) The initial transformation of the recombinant DNA of ProCA1s is
inserted through a heat shock method into the desired host cell strain.
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Figure 2.3 The expression scheme represents the stepwise method used for the tag-less ProCA1s’
overexpression in the four different E.coli competent cell strains.
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Figure 2.4 The denaturing and refolding steps are described in a detailed step-by-step method for the tag-less purification of each ProCA1s .
Four major steps highlight the procedure for the established denaturing-refolding purification of the tag-less ProCA1 charged variants.
Abbreviations: cell pellet (CP), supernatant (SN), overnight (o/n).
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Figure 2.5 The FPLC-Q column preparation scheme and programmed salt gradient.
The column is pre-washed with buffer A to remove any non-specific binding from previous usage. The
protein of interest, ProCA1s, presumably elute between 30 % and 70 % NaCl in two-milliliter fraction
volumes.
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2.3 Results and Discussion
2.3.1 Host cell strain influence on the expression of tag-less charged ProCA1 variants
Initially, a small-scale expression system measures the efficiency of three clones grown on the
agar plate for each cell strains. The cell strains BL21 (DE3), and Tuner are examples of the small-scale
expression system for ProCA1. All clones for BL21 (DE3) and Tuner demonstrate similar expression
intensity (Figure 2.6). The cell growth increases exponentially with time (minutes) for variants expressed
in BL21 (DE3) and Tuner in the small-scale expression system.
In the case of the large-scale expression system, it is relatively the same for all ProCA1 variants
aside from the host cell strain. The four E.coli cell strains have different necessities and demands during
the expression process. Thus, as a result different levels of expression are demonstrated in Figure 2.7.
Specifically, 7E15E and 7E15N demonstrate an exponential decay in Rosetta-gami (DE3) pLysS postinduction point range, which is between 500 - 1500 minutes. Similarly, 7E15N and 7E15Q show a
decrease in optical density after the induction point but 7E15N decreases at a larger fold than 7E15Q
during cultivation in BL21 (DE3) pLysS. The gradual increase in O.D. readings for the charged variants in
BL21 (DE3) gradually indicates a bacteria cell growth throughout the expression process. The low optical
density value between the one-hour and the overnight induction conditions affect 7E15E and 7E15N
expressed in Rosetta-gami (DE3) pLysS, suggested a decrease in cell growth. The growth curve and the
15% SDS-PAGE expression gels (Figure 2.7 a and b) support this occurrence. It was expected that an
increase in band thickness and intensity would be present for expression of the proteins after induction.
The results show otherwise for 7E15E and 7E15N, in Rosetta-gami (DE3) pLysS; and 7E15N and 7E15Q, in
BL21 (DE3) pLysS; after the induction process.
Expression of an unknown protein is indicated between 68 and 26 KDa markers from the one
liter 7E15Q post-induction sample that is cultivated in Rosetta-gami (DE3) pLysS (Figure 2.7 a). Thin
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bands of this unknown protein are also present at the same KDa position for 7E15E and 7E15N postinduction samples that are cultured in Rosetta-gami (DE3) pLysS. The expression process is low for the
charged variants in BL21 (DE3) cell strain, while low intensity bands are displayed for the proteins in
Rosetta-gami (DE3) pLysS. Little bacteria cell growth is indicated for proteins expressed in Rosetta-gami
(DE3) pLysS. Some experimental factors are considered for the influence on the low cultivation level in
Rosetta-gami (DE3) pLysS and BL21 (DE3) pLysS. In addition, the expression level for both E.coli strains
contains a T7 lysozyme; promoted from the pLysS marker, which hinders the excessive cell proliferation
prior to the induction step. This reasoning supports the exponential decay for some of the charged
variants expressed in BL21 (DE3) pLysS and Rosetta-gami (DE3) pLysS.

Figure 2.6 The growth curve for the small-scale expression of ProCA1 in a) BL21 (DE3), Tuner, and BL21
(DE3) pLysS (in 10 mL LB medium volume) b) with the corresponding 15% SDS-PAGE, and c) In
following, the low expression intensity for all three cell strains.
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Figure 2.7 The large-scale expression of ProCA1 variants and the corresponding growth curve for each
cell strain.
a) The successful and reproducible expression level is indicated for all ProCA1 variants growth in the
Tuner cell strain. b) Only 7E15E and 7E15Q are overexpressed at an optical density (2- 2.5) value
compared to 7E15N ( ~1 O.D.) during the growth in BL21 (DE3) pLysS. The overexpression of ProCA1
variants is suiTable in c) BL 21 (DE3) while unsuccessful expression level is indicated in Rosetta-gami
(DE3) pLysS with the corresponding intensity ratio. The protein of interested is highlighted in the
respective colored box (red for Tuner, orange for BL21 (DE3), and yellow for BL21 (DE3) pLysS) at a
~11.2 KDa molecular weight. The expression condition for all 3 host cell strain is the same (0.20 mM
IPTG, at 25 °C). ProCA1 charged variants have highest expression intensity ratio (1.00 for 7E15E, 0.84
for 7E15N, 1.33 for 7E15Q) in Tuner cell strain compared to the other expression ratio levels
quantified based on the pixel density of the protein band at ~ 11.2 KDa position.
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2.3.2 The denatured-refolding purification of tag-less charged ProCA1 variants
Each liter of expressed ProCA1 charged variants is treated through a set of denaturation and
refolding steps for purification from the inclusion body. The summarized gel samples during the
denaturing-refolding steps are demonstrated (Figure 2.8) for all charged variants expressed in BL21
(DE3), BL21 (DE3) pLysS, and Tuner. The cell pellets cultured (Figure 2.8) are lysed and the band intensity
of the protein of interest is visually compared in the supernatant (SN) and pellet (P). In BL21 (DE3), there
is a large intensity for all charged variants after the final refolding step in 10 mM HEPES dialysis buffer. In
addition, little ProCA1 charged variants are recovered after cell lysing since there was low expression
intensity in BL21 (DE3) pLysS and Rosetta-gami pLysS (Figure 2.8 b, c). In BL21 (DE3) pLysS, there is a
large contamination range at the high molecular weight but it is separated from the protein of interest
after the denaturing step in 8 M urea for overnight (Figure 2.8 b). Only 7E15E is successfully purified
from this host cell strain, where 7E15E (14.13 mg) has a higher yield than 7E15Q (0.16 mg) (Figure 2.9.b).
The ProCA1s ratio from supernatant to inclusion body after cell lysis varies for each ProCA1 charged
variants. 7E15E demonstrates a favorable intensity ratio in the pellet form while 7E15N and 7E15Q
demonstrate a favorable ratio in the supernatant form. These results suggest that the expression
conditions promoted the solubility for 7E15N and 7E15Q that are both -4 charged, compared to
insoluble 7E15E with a -5 charge. A second trial with the second liter demonstrates a similar
phenomenon but only for high solubility enhancement in 7E15Q, while 7E15E and 7E15N were in the
high insoluble ratio. These results rule out that the charged pocket has an effect on the conditions set
during expression in Tuner. Since there is a predominant ratio of ProCA1s in the supernatant and pellet
after cell lysis, both supernatant and refolded inclusion body are passed through the FPLC-Q column for
further isolation from contaminants (Figure 2.10).
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2.3.3 The refolded tag-less ProCA1 charged variants isolated by the FPLC Q-column anion
exchanger
The chromatographs (Figures 2.9 - 2.10) display the isolation of the charged variants through the
anion exchange column. 15 % SDS-PAGE confirms protein presence in peak two for all charged variants.
In addition, the UV-VIS spectra data are consistent with these results. The 15% SDS-PAGE of the
concentrated protein samples indicates successful protein isolation for 7E15E in BL21 (DE3) as an
example of protein isolation post refolding (Figure 2.9). Both dialysis samples and supernatant
sonication samples are run through the FPLC Q-column for flask one charged variants expressed in
Tuner. In the FPLC process for charged variants expressed in Tuner, the ProCA1 variants were isolated
for flask one. 7E15E protein is present in the isolated peak two (Figure 2.10 a). The 7E15N protein is
eluted in fractions of peak one and the same result is obtained for 7E15Q. These results from the
chromatogram and 15 % SDS-PAGE indicate an unsuccessful separation for 7E15N and 7E15Q in the SN
sonication sample. Sonication samples have DNA and other biological contaminants that may cause the
protein of interest to not elute with an increase in salt concentration throughout the FPLC application. A
high protein yield from two liters for each charged variants; 7E15E (19.30 mg/1L), 7E15N (61.48 mg/1L),
and 7E15Q (72.20 mg/1L), are displayed (Figure 2.11 c) for expression in Tuner.
Other components are present in the protein sample after concentration of peak two for 7E15E
and 7E15N expressed in BL21 (DE3). 7E15Q shows the lowest DNA presence based upon the absorbance
max ratio at 260 nm / 280 nm (Figure 2.11 a). For further purification to remove unwanted proteins
from the concentrated samples of 7E15E, we used a size-exclusion or gel filtration chromatography. As
shown in Figure 2.12, our protein of interest with a ~11.2 KDa was eluted out in fractions contained in
peak three. The percent intensity of the gel band is lower compared to the initial concentrated sample
(Figure 2.11 a). Tables in Figure 2.11 summarize the yield of the different variants with BL21 (DE3) pLysS
and Rosetta-gami (DE3) (DE3) pLysS, E. Coli cell strains. A low yield for CD2.7E15E (14.18 mg),
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CD2.7E15N (17.04 mg), and CD2.7E15Q (12.56 mg) were calculated (Figure 2.11 a) for expression in BL21
(DE3).

Figure 2.8 The 15 % SDS-PAGE for all ProCA1 variants are demonstrated for the tag-less refolding
method.
All protein variants are successfully recovered from the inclusion body post refolding method but all
display impurities at the high molecular weight region for a) BL21 (DE3) condition; while Rosetta-gami
(DE3) (DE3) pLysS confirms that no protein was produced during overexpression; b) only 7E15E is
recovered at high yield compared to 7E15Q and 7E15N from overexpression in the BL 21 (DE3) pLysS
condition; c) the over expression of 7E15Q and 7E15N are both in the supernatant (SN) post sonication
while 7E15E is mainly in the pellet (P). This leads to low recovery of 7E15N and 7E15Q from the CP
while 7E15E is recovered successfully in the SN.

46

Figure 2.9 The 7E15E variant is isolated through a FPLC system using an anion exchanger column (Q-column).
7E15E sample expressed from BL21 (DE3) demonstrates a high mAU in peak indicated by the arrow. The sample demonstrates nucleotide
contamination successfully isolated after the program gradient reaches 100 % salt concentration.
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Figure 2.10 Ion exchange FPLC Chromatograms of dialysis and sonication samples for the following proteins: a) 7E15E flask 1
Conditions are as follow: HiTrap 5 mL Q-column with cation beads, Pressure: 0.3 to 0.5 MPa, Flow rate: 3 mL/min Detector: UV lamp 280 nm
shows the presence of protein in peak 2 (for 7E15E dialysis sample)(confirmed by SDS-PAGE gels)
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Figure 2.11 The overall yield for each variant is summarized in correspondence to the cell strain
condition.
a) BL21 (DE3) cell strain gives successful yield for all three variants; b) BL21 (DE3) pLysS cell strain gives
a successful yield for 7E15E only while 7E15Q has a relatively low yield; c) Tuner cell strain gives a
relatively high yield for all three variants compared to the other three cell strains mentioned for the
expression system.
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Figure 2.12 Size-exclusion chromatography used for isolation of impurities from the concentrated
samples post refolding purification method.
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2.4 Conclusion and Future Work
The overall work in this Chapter are as follow: a) the small-scale expression of ProCA1 in two
different cell strains, b) the large scale expression of 7E15E, 7E15N, and 7E15Q in varying E.coli cell
strains, c) the refolding purification method applied to the large scale expressed variants, and d) The UVVisible absorbance spectrum and final yield in milligrams from each cell strain expression system.
Rosetta-gami (DE3) pLysS cell strain has the lowest yield in the protein expression system and
consequently no reasonable amounts of ProCA1 variants are obtained after cell lysing for the
purification. Loss of protein in the purification process that results in low yield is due to discarded
sonication samples during the purification method. Thus, as an optimizing condition, all supernatant
samples and cell pellet samples are conserved during the purification method for expressed variants in
Tuner. All waste should be conserved until the confirmation of protein presence by SDS-PAGE and UVVIS absorbance spectrum as a keynote. Little is known about the ProCA1s expression mechanism after
cell lysis. Surprisingly, Tuner promotes solubility in the cytoplasm at a high protein band intensity after
cell lysing so further optimization in Tuner cell strains for ProCA1s variants should be observed in terms
of change in IPTG concentration. Since Tuner promotes high expression in proportion to the increase
IPTG concentration, varying the IPTG concentrations during expression at a small scale is beneficial for
future analysis.
Protein expression and purification in Tuner indicates highest yield for all ProCA1s. Conclusions
based on expression and purification results seem to convey that BL21 (DE3) and Tuner induce
expression of the proteins of interest along with another protein of a higher molecular weight. The
nutrient rich LB medium may cause the co-expression of this unknown contaminant, thus other media
systems are considered as future work. BL21 (DE3) pLysS is the only cell strain that promotes low
expression of this high molecular weight contaminant. Further analysis is suggested on the expression
results of the charged variants by varying the temperature, medium system, and IPTG concentration for
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the expression system at a small-scale. Another consideration for the parameters in the purification
system is: changing the denaturant and using a lower concentration of that particular denaturant. In
addition, the determination of the folding ability of each variant in relation to the change in denaturant
concentration may be useful for continued optimization in the refolding method.
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3. OPTIMIZATION OF EXPRESSED AND PURIFIED GST-TAGGED PROCA1 VARIANTS
3. 1 Introduction
Glutathione S-transferase (GST) fusion system is widely used for large-scale protein production
[56]. This fusion system is chosen due to several advantages. First, it provides a purification tag for
generated protein. Second, the GST-tag at the N-terminal can be cleaved by thrombin during
purification. Third, GST helps protein fold correctly. We’ve taken the developed recombinant DNA
sequence of engineered ProCA1 and cloned it into a pGEX-2T vector containing a glutathione Stransferase (GST)-tag site. GST is a 26 KDa enzyme with a binding site that catalyzes the reduced
glutathione (GSH) (Figure 3.1) [57]. The monomer form of E.Coli GST is composed of two domains: 1)
thioredoxin-like domain with the GSH binding site (G site) and 2) the α-domain with the hydrophobic
binding site (H-site) (Figure 3.1 b) [58]. A known residue determined by Wang et al. have shown that
histidine at position 106 (His106) contributes to the catalytic activity in the binding site while cysteine at
position 10 predominantly contributes to the redox reaction of thiol/disulfide bond formation [58].
Thrombin is a ~ 32 KDa enzyme that recognizes a specific peptide sequence (e.g. Leu-Val-Pro-Arg-GlySer), and the cleavage site has been modified for further improvement of the protein yield [59].
Thrombin is preferred due to its effective cleavage of the GST-tag compared to other known cleaving
enzymes such as PreScission protease and Factor Xa. Applying the GST moiety to the N-terminus of
ProCA1 variants promotes an equivalent co-expression of ProCA1 variants. Essentially, ProCA1 tagged to
the GST moiety will subsequently co-express inside the host cell during cultivation. One study worked
with GST-tagged Interferon proteins, which naturally misfold as inclusion body in vivo; they were
successfully purified at 100-mg/L yield based on a set optimal production and purification method using
the GST-tag fusion system [59]. In comparison, ProCA1 holds a sTable structural conformation during
expression at specified conditions. One challenge during expression is the co-expression of free GST
present in the cultivation medium causes low (< 5 mg/L) yield after purification.
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In this Chapter, we aimed to overcome these challenges by analyzing different conditions for
establishing an optimal production and purification procedure that can generate a high yield output of
our final products ProCA1 variants using the GST-tag fusion system. The first part of this study is to
screen the expression conditions as a process to determine the optimal GST-tagged cultivation of
charged and targeted ProCA1 variants (Figure 3.2 a). The second part of this study is to find the optimal
lysis buffer during purification for promoting a higher yield of the cleaved or untagged ProCA1 variants
(Figure 3.2 b).
Sections 3.3.1.1 and 3.3.1.2 discuss the troubleshooting analysis of the small and large-scale
expression of GST-tagged ProCA1 variants. The small-scale system focuses on increasing the expression
level of GST-tagged ProCA1, 7E15E, and 7E15N, ProCA1.ZHER2: 342, and ProCA1.ZEGFR by changing host
cell strains. An advantage to the small-scale expression system is that it utilizes limited materials for data
collecting and results are concluded effectively since three different colonies can be chosen for the
expression of each charged variant. Later in this Section, the large-scale expression discusses the
impacts of the change in temperature, IPTG concentration, and/or host cell strains have on the
expression for CD2.WT, ProCA1, 7E15E, 7E15N, 7E15Q, ProCA1.ZHER2: 342, and ProCA1.ZEGFR.
ProCA1.ZHER2: 342 and ProCA1.ZEGFR are designed ProCA1 variants with a targeting moiety that binds
to HER2/neu and EGFR, respectively, on the surface of cancer cells. This novel designed targeted ProCA1
variant is analyzed for production through various expression conditions such as cell strain, post
induction temperature change and inducer concentration. The cell strains involved in this analysis are
listed as following: BL21 (DE3), BL21 (DE3) pLysS, and Tuner. The results for all ProCA1 variants
production are then summarized in a Table for ease of interpreting the data.
The GST-tag purification method is executed after determining the optimal condition in the
expression system for both charged and targeted ProCA1 variants (Section 3.3.2.1). The biggest
challenge for the purification of these GST tagged proteins is the partial folding of HST tag in the cell
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lysate which may hinder the effective binding of GST to GSH substrate. In no particular preference to the
expression intensity level, the cultivated pellets are suspended in the lysis buffer with optimized
conditions (Figure 3.2 b). Buffer A, which has 1 % sarcosyl cationic detergent, represents the
conventional lysis conditions currently in use in the lab. As an effort to increase the solubility, binding,
and oxidation state of the enzymatic pocket on the GST moiety, we modified buffer A by adding 0.05%
triton x-100, a nonionic detergent, increasing the EDTA concentration, and adding DTT reducing reagent.
This modification is named cell lysis buffer B. Studies have shown that sarcosyl/triton x-100 detergent
ratio of 1:2 benefits in efficient GST catalytic activity and binding to the immobilized GSH substrate in an
affinity chromatography column [60-61]. In addition, the chelating factor of EDTA also influence in the
solubilization of the protein fusion by promoting peptidoglycan cleavage of the outer cell membrane
wall [62]. This reaction weakens the bonds to hold the cell wall intact and makes it easier for protein to
excrete out of the host cell during the lyses process. The mechanical and biological methods for cell lysis
are considered. The protein of interest is cultured in the E.Coli host cell and it is crucial that a particular
method and time duration for cell lysis are effectively applied for favorable GST-fusion protein solubility
into the supernatant. Sonicator, french press, and cell disruptor are the three commonly used
instruments in the lab for the protein extraction from the host cell. These mechanical methods have a
drawback, which is producing heat to the protein sample. This effect may cause partial unfolding of the
protein and then aggregates as inclusion body. Thus, the longer the cell is disrupted under harsh
conditions, the more likely that the protein of interest develops into inclusion body. The goal of this
study is to identify the best condition in the cell lysis buffer that is most beneficial for protein extraction
into the supernatant environment and that promotes effective enzymatic activity of the GST-tag moiety
for an increased yield production after Glutathione Sepharose-4 Beads column purification (Figure 3.2
b).
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Both supernatant and refolded inclusion body GST-tagged proteins are applied to the GS-4B
column during the purification for achieving an increased yield. Due to a large amount of the fusion
protein present as inclusion body after cell lysis, one focus is directed at decreasing the percent of GSTtagged ProCA1 present as inclusion body. Völkel et al successfully recovered inclusion body into folded,
soluble, and bioactive protein with full-length by using a denaturing-refolding method with a His-tag
then followed by a GST-tag purification system [63]. Essentially, I applied a similar procedure to recover
the initial GST-tagged proteins from the insoluble inclusion body form.
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Figure 3.1 The schematic representation of the GST-tag ProCA1 and ProCA1.affi342.
The N-terminal fusion is a) the typical tag design used for GST-fusion partners. b) Cartoons of all three
moieties displayed in this scheme are: GST bound to GSH, CD2.7E15 free form (ProCA1), and ZHER2:
342-affibody peptide targeted towards HER2/neu biomarkers. The following are the pdb codes used
to generate the cartoon for GST-GSH (1AQW), CD2.7E15 (1hng), and affibody ZHER2: 342 (2KZI)
through PyMOL[30].
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Figure 3.2 The specific parameters for optimizing the expression yield of GST-tagged ProCA1 variants.
The selected three parameters are essential for the expression yield of the GST-tagged ProCA1
variants. The inducer concentration refers to the IPTG amount (mM) added to each one liter LB
medium with treatment of 0.10 mM ampicillin. The temperature adjustment during and after the
adding of IPTG is important for the optical density of the media, which is directly related with the
protein yield. There are various E. Coli host cell strains (Table 2.2) with specific mutations that enable
the synthesis of the recombinant DNA sequence of our ProCAs within the cytoplasm. The growth of
the cell strains depends on the temperature environment, specified IPTG concentration, and the
characteristic of the protein of interest that is synthesized in the host cell strain.
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Figure 3.3 The outlined steps for optimizing the parameters in the purification system of the GST-tagged ProCA1 variants.
Both ProCA1 charged / targeted variants are tested in this optimizing scheme that aims to increase the yield of each protein of interest.
Specifically, modification of lysis buffer A conditions is important to the protein yield after GS- 4B column purification. DTT, Triton X-100, and
increased EDTA are added as a modification to lysis buffer A and relabed as lysis buffer B. Lysozyme is then added to test whether the less
harsh lysing process of the cell will generate less aggregation of the ProCA1 as inclusion body and this modification is labeled lysis buffer C.
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3.2 Methods
3.2.1 Transformation
The following E. Coli cell strains, (BL21 (DE3), BL21 (DE3) pLysS, and/or Tuner, were allowed to
thaw in an ice along with the CD2.7E15 (or ProCA1) variant DNA plasmids/ pGEX-2T vector. This was
proceeded the same for all other five ProCA1 variants, both charged and targeted. Further details of this
procedure are available in Chapter 2 experimental Section 2.2.2. Note: all proteins expressed in this
Chapter 3 use the GST-tag vector pGEX-2T (Figure 3.3).
3.2.2 Small-scale and large-scale expression of GST-tag ProCA1 variants
The small- scale expression was conducted in small falcon tubes (50 mL capacity and 15 mL
capacity) rather than glass flask. The expressed samples are collected and 15% SDS-PAGE was used for
analysis of purity. Refer to the experimental Section 2.2.3 of Chapter 2 for the small and large scale
expression details.
3.2.3 GST-tag gravity column purification
Cell pellets of all variants were collected after overexpression and thawed on ice at room
temperature for an hour. The cell pellet was then suspended in a lysis detergent (20 mL) along with 2
mM Mg2+ (100 μL) and benzonase nuclease (1 μL) for DNA cleavage, named lysis buffer A. The lysis
buffer with the protein was constantly mixed in a falcon tube with a vortex. Once the solution was
homogeneous then the solution was applied through either a cell disrupter (3X) or French press (3X)
until the solution was clear and less viscous in appearance. The solution was placed in centrifuged tubes
for sedimentation for 30 minutes at 17K rpm speed. The supernatant and cell pellet were taken for SDSPAGE analysis. The supernatant was filtered with a 0.45 μM membrane filter and then passed through a
gravity affinity column with glutathione-coated sepharose beads (~5 mL). The supernatant was passed
through the column twice then rinsed with phosphate buffered saline (1X PBS) until the beads turned
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clear white. After the binding step, 200 μL of stock thrombin (1 mg/mL) was added to the column
suspended in 1X PBS. The final thrombin concentration is 0.04 mg/mL. Then, the column was shaked at
4 °C for overnight cleavage. The next day, the column was placed on the shaker at room temperature for
another hour. The protein solution was then eluted out of the column with consecutive shaking in PBS
buffer in following a second elution. The eluted samples were collected for SDS and UV-Vis absorbance
were measured at 280 nm.
For a similar protocol which involves in the use of lysozyme labeled as lysis buffer C, the
procedures are as following: First, the cell pellet was thawed with lysate buffer C by adding 1-1.5 mM
MgCl2, 5 mM DTT, 1% N-lauryl Sarcosine and one Tablet of protease inhibitor per 100 mL lysis buffer
volume. Second, a magnetic stir bar was used to suspend the cell pellet in the lysis solution instead of
vortex. Third, lysozyme was added at a ratio depending on volume of cell pellet used (300 mg per 3L
culture medium) so 100 mg of cell pellet from each liter of medium. Fourth, lysate solution of cell pellets
with the lysozyme was left on ice for 1 to 2 hours. Sonication for 1 minute may be used if needed.
Finally, the sample was centrifuged at high speed and supernatant was collected and filtered. The
sample was (clear and not viscous in appearance after this step. The volume started with 30 mL and
doubles to 70-80 mL after all the above steps. Then the supernatant sample was passed through the GS4B column. The total volume of sample is 6 to 10 times of the column volume because of the column
capacity and efficacy.
3.2.4 Refolding of GST-tagged ProCA1 variants
The over-expressed cells containing the GST-tag ProCA1 variants were lysed by mechanical
methods (i.e. sonication, French press, cell disruption). After lysating the cell, the insoluble form of the
protein aggregated as inclusion body (IB). This insoluble form was washed with the lysis buffer B
consisting of 10 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, 5 mM DTT. After centrifugation at 17 Krpm,
the pellet was solubilized in buffer containing 20 mM Na3PO4, pH 7.0, 8 M urea, and 100 mM 2-
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mercaptoethanol. The dissolving step is to stir the sample at room temperature for an hour in the
mentioned buffer. The sample was centrifuged again and the supernatant was collected at this stage of
the purification. The supernatant was diluted to two fold the original volume of the buffer (10 mM
Na3PO4, pH 7.0, 4 M urea, and 50 mM 2-mercaptoethanol) and left stirring either overnight or 4hrs at 4
°C. The sample was dialyzed to remove urea and β- mercapto-ethanol. Then the sample will be filtered
and loaded into the GS-4B column by using the established protocol.
3.2.5 FPLC - cation exchange SP - column and ultrafiltration application
Fast Protein Liquid Chromatography (FPLC, GE, and #INV-907, made in Sweden) was a
chromatographic process in which the protein in solution was exposed to a pH gradient system using a
SP cation exchange column. The FPLC system was first cleaned with ultra-pure deionized water (ddH2O).
Then 50 mM Sodium Acetate (NaOAC) buffer (pH ≈ 4.0) and 50 mM Tris buffer (pH ≈ 8.0) were prepared
and used as Buffer A and Buffer B, respectively. The column was gradually washed with the high pH
buffer B so protein was eluted out of the column and separated from other contaminants and thrombin
protease from the GST-tag column purification. The isoelectric point (pI) values of the variants are
similar and are intended to elute out at pH 7.2- pH: 7.4 (Figure 3.16, 3.21). Amicon ultrafiltration
pressure cell was used to increase the concentration of the purified protein solution. Inert Nitrogen gas
applied pressure to the protein solution, thus causing elution of smaller molecules in solution. The
membrane filter capacity (< 3.0 KDa) prevents the protein of interest and other biological molecules
with a larger molecular weight from filtering out as waste.
3.2.6 Quantifying the SDS-PAGE results of the GST-tag purification
The SDS-PAGE results were quantified by taking the intensity ratio of the supernatant against
the other sample band intensities (Figure 3.10 and Figure 3.11) through an Image J software (1.47v,
Rasband, Wayne, NIH, USA). The supernatant from lane 2 in the GST-tag purification for ProCA1, 7E15E,
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7E15N, and 7E15Q were normalized to 1 and were used as a reference to compare with the other
intensity values taken from the other samples throughout the purification process. Essentially, the initial
intensity value for the supernatant was divided by itself and all other intensity values from the other list
of samples. The indicated range below the graph demonstrates how the density of the samples
compares to the intensity of the supernatant. As a disclaimer: each band represents a 10-μL-volume
sample loaded into the SDS-PAGE. Thus, it is assumed that all protein band intensity come from an
equivalent volume that are quantified using image J software .The higher the ratio to one indicates that
there is a similar or higher band density compared to the supernatant and vice versa.
As a general note, I must state that the summarized intensity ratios quantified in Figure 3.10,
Figure 3.11, Figure 3.15, and Figure 3.17, have no error bars since the intensity ratio is based on one
band intensity value. The purpose of the band intensity charts is to identify the actual percent of the
protein in the supernatant versus the inclusion body form after cell lyses. In addition, the percent of
soluble form of the protein is also compared to the GSH-GST-ProCA1 complex amount inside the
column, the GST-ProCA1 complex, and the GST-free amount after the column is treated with phosphate
buffer saline (1X PBS). The percent ratio determines the amount of bound GST-tagged ProCA1 variants
that contributes to the final yield of the protein eluted out of the column after enzymatic cleavage with
thrombin. Several of these factors are analyzed by comparing the intensity ratio of each band based on
the set lysis buffer conditions. Basically, the detailed analysis of these intensity ratios indicate whether
the change in the lysis buffer conditions have an impact on each factor such as the bound/free form of
GST-ProCA1 amount to the beads.
3.2.7 Western-Blot and SDS-PAGE
Western blot assay was used to locate the position of ProCA1 in the gel. Regular 15 % SDS-PAGE
gel was run with the samples. Then self-generated rabbit antibody against rat ProCA1 was used as the
primary antibody. AP labeled polyclonal antibody was used as the secondary antibody. The 15 % SDS-
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PAGE was transferred for two hours or overnight followed by the blocking and antibody incubation
steps. Finally, the membrane was treated with enhancer and substrate for imaging. The instructions
were similar to Fan Pu’s established protocol based on the commercially available procedure [64].
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Figure 3.4 The commercially available pGEX-2T plasmid vector [55] has a GST promoter site before the
Eco RI site.
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Figure 3.5 The scheme for GS-4B column purification of GST-tagged ProCA1 variants.
All ProCA1 variants are purified by using the four steps illustrated above for the GST-tag purification method and the sample abbreviations
are indicated on the right panel of the scheme for clarification. Each eluted ProCA1 mutant is combined and passed through an SP-cation
exchange column with an adjusted pH at ~ 3 to 4 to remove excess thrombin and other possible contaminants after GS-4B column
purification.
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Figure 3.6 The refolding procedure of the inclusion body (IB) of GST-tagged ProCA1 variants.
This procedure is divided into four steps where the GST-tag ProCA1s are denatured then refolded back
into the soluble form. The recycled supernant holds unbound GST-tag ProCA1 that is collected as flow
though from the initial GS-4B column purification. This sample is labeled as beads after binding outside the column (BAB-OC). The sample is treated with steps 3 to 4 to serve as a recovery of the GST
moiety’s catalytic activity to bind to the reduced glutathione on the beads in the column.
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3.3 Results and Discussion
3.3.1 Expression of GST-tagged CD2.WT, ProCA1, and ProCA1 variants
3.3.1.1 Reliability of quantifying the protein bands using Image J software
The molecular weight of the GST-tagged ProCA1s is at a high position on the gel where there is
more congestion. Some uncertainties to this is that the current yield in the expression intensity may be
including other protein bands due to the fact that other background is present on the gel. This arbitrary
or error is not necessarily relevant to the final purification yield. During purification, a final single protein
band is observed as opposed to the heavy set of protein band on the expression gel’s background.
Quantifying the protein band from the expression samples are estimated by the assumed protein
molecular weight between 68 and 26 KDa protein markers.
3.3.1.2 The host cell strain effect on the small-scale expression of GST-tagged/charged ProCA1s
During the expression procedure in the small-scale system, exponential increases of optical
density were observed (Figure 3.6 a and b) for ProCA1, 7E15E, and 7E15N. The small-scale expression is
used to detect a clone or transformant that has the highest expression. In this system, 7E15E
demonstrates highest expression level in terms of the intensity ratio and is used as a reference against
the other intensity values obtained from the other protein samples. BL21 (DE3) pLysS is highest in
expression level for GST-tag 7E15E, while BL21 (DE3) (79 %) and Tuner (92 %) demonstrate lower
expression level. For the case of 7E15N, the intensity values are fairly similar in range percentage as
observed in BL21 (DE3) (93 %), BL21 (DE3) pLysS (91 %) and Tuner (90 %). There is no conclusive
indication that either of the three cell strains tested is most suiTable for best cultivation level, solely
based on the similar intensity values. Therefore GST-tag 7E15N can be successfully expressed at a similar
cultivation level in either of the three cell strains mentioned earlier. For the case of GST-tag 7E15E, there
is an indication that GST-fusion protein is expressed with a highest cell culture level in BL21 (DE3) pLysS.
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The increased expression level in BL21 (DE3) is predominant for GST-tagged ProCA1 as compared to the
low intensity value in BL21 (DE3) pLysS (90 %).
3.3.1.3 The effect of host cell strain, post-induction temperature, and IPTG concentration on the
expression yield of CD2.WT
The optical density value varies as a function of time monitored at 600 nm during the large-scale
expression in a one-liter LB medium. For GST-CD2.WT, there is a wide range in optical density value post
induction time, which is between 1000 to 1500 minutes (Figure 3.7). This phenomenon suggests possible
growth difference for each one-liter flask. Tuner cells demonstrate the most saturation in terms of
protein band present within the 26 to 68 KDa regions. In following, the percent intensity is measured in
correspondence to the 15% SDS-PAGE of the samples collected prior to collecting the expressed cells.
The host cell strain involved in the large-scale expression of CD2.WT is BL21 (DE3) and Tuner. The
highest intensity percentage with cells expressed in Tuner (0.30 mM IPTG at 30 °C overnight) is used as
the intensity reference. The percent intensity value for cells cultured in BL21 (DE3) (0.30 mM IPTG)
increases during overnight induction at 30 °C, and 25 °C (76 %, 72 %), respectively. Low expression is
indicated during a five-hour induction period at 37 °C (58 %) in the same cell strain and inducer
concentration. A longer induction time shows high expression of GST-tagged CD2.WT.
3.3.1.4 The effect of host cell strain, post-induction temperature, and IPTG concentration on the
expression yield of ProCA1
GST-tagged ProCA1 demonstrates the overall highest optical density value with 0.30 mM IPTG at
25 °C in flask 3 (Figure 3.8 a). The expression conditions are separated by cell strain (BL21 (DE3), BL21
(DE3) pLysS, Tuner), IPTG concentration (0.10 to 0.35 mM), and temperature post induction (25 °C, 37
°C) for this large-scale expression. The optical density values are all calculated based on the diluted
overnight culture samples to satisfy the optical density range recorded by the UV-vis spectrophotometer
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(0.1 to 1). The dilution factor is then used to determine the actual O.D. These values range from ~3 to
~16 for overnight expression at 25 °C while there is a narrow range from ~2 to ~6 optical density post
induction at 37 °C. It is typical to decrease the temperature during overnight cultivation to promote
gradual expression growth of the protein in the cytoplasm. The cell cultured at high temperature
demonstrates a lower optical density, which may suggest low expression of the cells containing GSTtagged ProCA1. The protein bands are demonstrated at ~37.2 KDa for expression with 0.30 mM IPTG at
37 °C in BL21 (DE3) cells and used as the reference which shows highest overall expression (Figure 3.8 c,
e). Expression levels fluctuate from a decreased to increased then back to a decreased intensity ratio
with respect to the increased IPTG concentration at a fixed temperature (37 °C) (i.e. 0.10 mM, 66%, 0.20
mM 59 %, 0.30 mM, 100%, and 0.35 mM, 83%) in BL21 (DE3). GST-tagged ProCA1 is suiTable for high
expression at high IPTG concentration during an overnight induction period at 25 °C (i.e. 0.10 mM, 46 %,
and 0.30 mM 54 %). At a 25 °C post induction temperature, the cultivation level increased by 74 % in
BL21 (DE3) pLysS with a low IPTG concentration (0.10 mM) as compared to a decrease in BL21 (DE3). In
the same expression conditions, Tuner cells shows highest culture level compared to BL21 (DE3) (Figure
3.8 c, e).
3.3.1.5 The effect of post-induction temperature, and IPTG concentration for 7E15E, 7E15N, and
7E15Q
GST-tagged 7E15E, 7E15N, and 7E15Q are all expressed in same E.coli host cell, BL21 (DE3). The
overall highest culture for all three charged variants is shown in a 0.20 mM IPTG concentration during
overnight induction at 25 °C. There is fluctuation with the expression level intensity ratio versus the IPTG
concentration. The increased intensity ratio from 0.10 mM (58%) to 0.20 mM (100%) is observed but a
sharp decrease occurs at the higher inducer concentrations (i.e. 0.30 mM, 72%, and 0.35 mM, 34 %) in
25 °C temperature for GST-tagged 7E15E. In terms of the fixed inducer concentration (0.10 mM), there is
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no significant change in the expression level as the intensity ratios are similar in value (i.e. 25 °C, 58 %,
and 37°C, 53 %) during the different cultivation temperatures (Figure 3.8 f). Similar to GST-tagged 7E15E,
the expression output of GST-tagged 7E15N increased from 73 % (0.10 mM) to 100 % (0.20 mM) but
then decreased from 77 % (0.30 mM) to 48 % (0.35 mM). At the constant IPTG concentration (0.10 mM),
the expression level decreased from 73 % (25 °C) to 58 % (37 °C) with respect to the induction
temperature (Figure 3.9 e). For GST-tagged 7E15Q, as the inducer concentration decreased, i.e. 0.35
mM, 0.30 mM, 0.20 mM; the intensity ratio increased (49 %, 70 %, 100 %) respectively, during a 25 °C
overnight expression temperature (Figure 3.9 f).
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Figure 3.7 The small-scale expression of GST-tagged CD2.7E15E, CD2.7E15N, and ProCA1.
a) The small-scale expression of CD2.7E15E and CD2.7E15N/pGEX-2T in BL21 (DE3), Tuner, and BL21 (DE3) pLysS shows an increased
exponential growth as demonstrated by the optical density curve. b) As a control, the optical density in the small-scale expression of
ProCA1/pGEX-2T in BL21 (DE3) pLysS and BL21 (DE3) are plotted as a function of time (min). c) The 15 % SDS-PAGE demonstrates the band
intensity at ~37.2 KDa for CD2.7E15E, CD2.7E15N, and d) ProCA1. e) The percent band intensity are averaged and compared for each charged
variants with the corresponding expressed cell strain for 7E15E, 7E15N, and f) ProCA1. Abbreviations are as follow: BL21 (DE3) (BL), Tuner (T),
BL21 (DE3) pLysS (BP), 7E15E (E), 7E15N (N). Disclaimer: the quantified protein band intensity ratio base on the pixel density are a rough
estimation due to the estimated molecular weight for each ProCA1 variants at ~ 37.2 KDa .
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Figure 3.8 The large-scale expression of GST-tagged CD2.D1 wild type
a) The large-scale expression of CD2.WT/pGEX-2T in BL21 (DE3), and Tuner shows an increased
exponential growth as demonstrated by the optical density curve. b) The 15% SDS-PAGE demonstrates
the band intensity at ~38 KDa for all expression conditions. c) Each percent band intensity is compared
with the corresponding expressed cell strain, temperature and IPTG concentration (mM).
Abbreviations are as follow: BL21 (DE3) (BL), Tuner (T), overnight (o/n), wild type (WT). Disclaimer:
the quantified protein band intensity ratio base on the pixel density are a rough estimation due to the
estimated molecular weight for each ProCA1 variants at ~ 38 KDa
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Figure 3.9 The large-scale expression of GST-tagged ProCA1 and CD2.7E15E at varying cell strains, IPTG concentration, and/or induction
temperature.
a) The large-scale expression of ProCA1/pGEX-2T and b) CD2.7E15E/pGEX-2T in BL21 (DE3) shows an increased exponential growth as
demonstrated by the optical density curve. c) The 15% SDS-PAGE for ProCA1and d) E demonstrates the band intensity at ~37.2 KDa for all
expression conditions. e) Each percent band intensity for ProCA1 and f) E are compared with the corresponding expressed cell strain,
temperature and IPTG concentration (mM). Abbreviations are as follow: BL21 (DE3) (BL), BL21 (DE3) (BL), BL21 (DE3) pLysS (BLpLsS), Tuner
(T), overnight (o/n).
Disclaimer: the quantified protein band intensity ratio base on the pixel density are a rough estimation due to the estimated molecular
weight for each ProCA1 variants at ~ 37.2 KDa
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Figure 3.10 The large-scale expression of GST-tag CD2.7E15N and CD2.7E15Q at varying IPTG concentration and induction temperature.
a) The large-scale expression of CD2.7E15N/pGEX-2T and b) CD2.7E15Q/pGEX-2T in BL21 (DE3) shows an increased exponential growth as
demonstrated by the optical density curve. c) The 15% SDS-PAGE for N and d) Q demonstrates the band intensity at ~37.2 KDa for all
expression conditions. e) Each percent band intensity for N and f) Q are compared with the corresponding expressed cell strain, temperature
and IPTG concentration (mM). Abbreviations are as follow: BL21 (DE3) (BL), overnight (o/n). Disclaimer: the quantified protein band intensity
ratio base on the pixel density are a rough estimation due to the estimated molecular weight for each ProCA1 variants at ~ 37.2 KDa.
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3.3.1.6 The effect of host cell strain on the small-scale expression yield of GST-tagged HER2 –
targeted ProCA1
As discussed previously, the small-scale expression system allows for multiple trial analyses.
Thus, expression conditions in terms of cell strains can be troubleshoot. The expression of the targeted
ProCA1 is monitored simultaneously in both BL21 (DE3) and BL21 (DE3) pLysS. Both targeted ProCA1
variants display an increased exponential growth in accordance for all three trials corresponding to the
two host cell strains. The final optical density ranges from 1.5 to 2 at 600 nm wavelength post overnight
growth at 25 °C with a 5 mL LB media. In following, the percent intensity from the bands displayed on
the 15% SDS-PAGE gels is compared and the cell strain which promotes the highest expression is
observed for ProCA1.ZHER2: 342 and ProCA1.ZEGFR: 1907. The small-scale expression for the GST-tag
targeted ProCA1.affi1907 is cultured at a high density in BL21 (DE3) (Figure 3.10). ProCA1.affi.HER2: 342
in the contrary is expressed in BL21 (DE3) (93 %) and BL21 (DE3) pLysS (94 %) at a similar intensity
amount to ProCA1.affi1907 expressed in BL21 (DE3) pLysS.
3.3.1.7 The effect of host cell strain, post-induction temperature, and IPTG concentration on the
large-scale expression yield of GST-tagged HER2/neu ProCA1 (ProCA1.affi342)
In the large-scale expression system, the overall highest intensity ratio is represented in the
following expression condition for GST-tag ProCA1.affi342: 0.35 mM IPTG at 37 °C in BL21 (DE3) cells
(Figure 3.11). Gradual increase in the intensity ratio (66, 70, 100 %) is observed in respect to the
increase IPTG concentration (0.10, 0.30, 0.35 mM) with the exception of a gradual 20 % decrease
observed at the highest IPTG concentration (i.e. 0.40 mM, BL21 (DE3), 80 %). An increase in the
induction time at a lower induction temperature as compared to the shorter induction time period at
the higher induction temperature demonstrate a decreased intensity ratio for cells expressed in BL21
(DE3) at a fixed 0.10 mM IPTG concentration. In the contrary, there is highest intensity ratio at 37 °C (96
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%) compared to the overnight 25 °C (68 %) induction period for GST-tag ProCA1.affi342 expressed in
BL21 (DE3) pLysS. The same intensity ratio is observed for GST-tag ProCA1.affi342 expressed at 37 °C in
Tuner (70 %) (0.20 mM IPTG) and BL21 (DE3) (0.30 mM IPTG).
3.3.1.8 The effect of host cell strain, post-induction temperature, and IPTG concentration on the
large-scale expression yield of GST-tagged EGFR ProCA1 (ProCA1.affi1907)
The highest cultivation level is observed when GST-ProCA1.affi1907 is expressed in the following
conditions: 0.10 mM IPTG, at 37°C in BL21 (DE3) pLysS. In terms of the fixed BL21 (DE3) cell strain, the
increased intensity ratio is proportional to the increased IPTG concentration, i.e. 0.10 mM (46%) to 0.35
mM (93 %); but a sharp decrease is observed at the highest 0.40 mM (36 %) IPTG concentration (Figure
3.12). In terms of a fixed 0.10 mM IPTG concentration, the expression intensity level decreased, i.e. 54 %
(at 25 °C) to 46 % (at 37 °C), with respect to the increased induction temperature in BL21 (DE3) cells. In
the contrary, an increased expression intensity as a function of an increased induction temperature is
observed in BL21 (DE3) pLysS cells. These results are consistent with those obtained for expression of
GST-tagged ProCA1.affi342 and ProCA1.affi1907. GST-tag ProCA1.affi1907 increased in expression by 77
% in Tuner cells at 37 °C with 0.20 mM IPTG (Figure 3.12 c).
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Figure 3.11 The small-scale expression of GST-tag ProCA1.ZHER: 342 and ProCA1.ZEGFR:1907
a) The small-scale expression of ProCA1.ZHER: 342 and ProCA1.ZEGFR:1907 PGEX-2T in BL21 (DE3), and BL21
(DE3) pLysS shows an increased exponential growth as demonstrated by the optical density curve. b)
The 15% SDS-PAGE demonstrates the band intensity at ~44 KDa for both ProCA1.ZHER:342 and
ProCA1.ZEGFR:1907 . c) The percent band intensity are averaged and compared for each charged variants
with the corresponding expressed cell strain along side the standard error bar. Abbreviations are as
follow: BL21 (DE3) (BL), BL21 (DE3) pLysS (BLpLsS), ProCA1.ZHER2:342 (HR342 or Z HER2:342),
ProCA1.ZEGFR:1907 (EGFR-1907 or ZEGFR:1907). Disclaimer: the quantified protein band intensity ratio
base on the pixel density are a rough estimation due to the estimated molecular weight for each
ProCA1 variants at ~ 44 KDa
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Figure 3.12 The large-scale expression of GST-tagged ProCA1.ZHER2:342 at varying cell strains, IPTG
concentration, and induction temperature.
a) The 15% SDS-PAGE demonstrate the band intensity at ~44 KDa for all expression conditions. b) The
large-scale expression of ProCA1.ZHER2: 342/pGEX-2T in BL21 (DE3), BL21 (DE3) pLysS, and Tuner
shows an increased exponential growth as demonstrated by the optical density curve. c) Each percent
band intensity is compared with the corresponding expressed cell strain, temperature and IPTG
concentration (mM). Abbreviations are as follow: BL21 (DE3) (BL), BL21 (DE3) pLysS (BLpLsS), Tuner
(T), overnight (o/n). Disclaimer: the quantified protein band intensity ratio base on the pixel density
are a rough estimation due to the estimated molecular weight for each ProCA1 variants at ~ 44 KDa.
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Figure 3.13 The large-scale expression of GST-tag ProCA1.ZEGFR: 1907 at varying cell strains, IPTG
concentration, and induction temperature.
a) The 15% SDS-PAGE demonstrate the band intensity at ~44 KDa for all expression conditions. b) The
large-scale expression of ProCA1.ZEGFR: 1907/pGEX-2T in BL21 (DE3), BL21 (DE3) pLysS, and Tuner
shows an increased exponential growth as demonstrated by the optical density curve. c) The percent
band intensity is compared with the corresponding expressed cell strain, temperature and IPTG
concentration (mM). Abbreviations are as follow: BL21 (DE3) (BL), BL21 (DE3) pLysS (BLpLsS), Tuner
(T), overnight (o/n). Disclaimer: the quantified protein band intensity ratio base on the pixel density
are a rough estimation due to the estimated molecular weight for each ProCA1 variants at ~ 44 KDa.
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3.3.2 Purification of GST-tag CD2.WT, ProCA1, and ProCA1 variants
3.3.2.1 The effect of lysis buffer conditions on the GST-tag ProCA1 charged variants
The following 15 % SDS-PAGE is a compilation of the results for the GST-tag purification (Figure
3.13). Each column represents the samples taken based on the set lysis buffer conditions. For instance,
the supernatant sample and the inclusion body sample represent the soluble and insoluble form,
respectively, of the protein after cell disruption. The specific intensity ratio for these bands are
compared (Figure 3.14) .The sample lane of the protein solution for beads after binding outside the
column (BAB-OC) represents the combination of the free contaminants, the GST-tagged ProCA, and the
GST-free components in lane four (Figure 3.13). The sample lane of the protein solution for beads after
binding inside the column (BAB-IC) indicates the density amount of bound GST-tag ProCA1 charged
variants to the glutathione coated beads. There is successful binding of the GST-tag proteins with the
beads based on the demonstrated protein band at ~ 37.2 KDa. In addition, the free eluted GST moiety at
26 KDa suggest that successful binding of the GST-tag proteins occurred during the purification process.
Lane 8 demonstrates the eluted free GST after the column is treated with a high concentration of free
glutathione in the reduced form. Overall, each GST-tag ProCA1 variant has a band density at ~37.2 KDa
from the corresponding lane numbers (1, 2, 4, and 5) and are quantified based on their intensity (Figure
3.14). ProCA1, CD2.7E15E, CD2.7E15N, and CD2.7E15Q are eluted out successfully as indicated by the
protein band at ~ 11.2 KDa in lane 7. The strongest band intensity represents the concentration of
successful eluted free ProCA1 charged variants for the lysis buffer with lysozyme and the established
method used from previous results in Natalie White’s Thesis [34]. There is successful purification of all
ProCA1 charged variants treated with the three different cell lysis buffers. This is an important concept
to grasp when analyzing the compilation of these SDS-PAGE results (Figure 3.13).
GST-7E15E binds successfully to the beads (BAB-IC, 110 %) but a portion of the fusion protein is
left unbound (BAB-OC, 57 %). 67% of the GST-7E15E is unfolded or aggregated as inclusion body after
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cell lysis. As a result, only 27 % of 7E15E is eluted after enzyme cleavage with thrombin. The low
percentage in elution is a result of inefficient binding of the GST-tag protein during the binding process,
which consists of the beads being treated in a consecutive wash with the supernatant. All these results
correspond to the GST-7E15E sample treated with lysis buffer A. One factor to consider is the increase in
the binding efficiency between the beads and the GST-tag protein by extending this binding process.
Other considerations are further discussed in the summarized Section for the GST-tag purification of
both charged and targeted ProCA1 variants (Figure 3.22). In the lysis buffer B condition, GST-7E15E is in
the inclusion body compared to the supernatant. A decrease in the beads binding to GST-7E15E is
suggested as a result of the percentage between BAB-Outside Column sample (99 %) and BAB-Inside
Column sample (54 %) in reference to the supernatant intensity ratio. The eluted GST- free moiety (51
%) represents the percent bound of the GST-GSH complex that was left post the enzymatic cleavage
process. These results suggest that binding is not effective after the minor modification of some
parameters in the lysis buffer A. GST-7E15E was not treated with lysis buffer C, so GST-ProCA1 is used as
an example of a charged variant with a -5 charged binding pocket, and the results are analyzed in
comparison to GST-7E15N and GST-7E15Q which carry a -4 charged binding pocket. GST-ProCA1, treated
with lysis buffer C, has less aggregation or unfolding as inclusion body (43 %). The binding efficiency
between the beads and the fusion protein increased when comparing the percent intensity for samples
labeled as BAB-OC (88 %) and BAB-IC. Although there is an increase to form the GSH-GST-ProCA1
complex inside the column, only approximately half of the protein is eluted (53 %) after enzyme
cleavage with respect to the initial protein amount present in the supernatant sample. The eluted GSTfree (29 %) represents the successful binding of GSH-GST-ProCA1 prior to enzyme cleavage. There is a
possibility that leftover GSH-GST is present inside the column because of the low percent intensity of the
sample labeled BAE compared to the elution.
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The soluble and insoluble portion of GST-7E15N (IB, 93 %) and GST-7E15Q (96 %) are similar in
intensity value after cell lysing with treatment of the lysis buffer A. The binding efficiency for the GST-tag
proteins to bind onto the GS 4 beads are analyzed by comparing the intensity ratio for samples labeled
as BAB-OC and BAB-IC. The GST-proteins bind successfully, but a similar portion of the unbound protein
fusion is present in the flow though after the binding process. BAB-OC (101 %, 52 %) and BAB-IC (84 %,
52 %) samples demonstrate a small difference in intensity ratio for GST-7E15N and GST-7E15Q,
respectively. This observation suggests that binding is effective to a certain extent, meaning that we
need to consider the beads capacity limit for complex formation to occur with the GST-tag moiety of the
protein during the binding process. For the case of cell lysing with the lysis buffer B, GST-7E15N and GST7E15Q have similar soluble/insoluble ratio when comparing the SN and IB intensity ratios. The intensity
ratio increases for BAB-OC sample while it decreases for BAB-IC. GST-7E15Q (BAB-IC, 87 %) forms
complex with GSH at a similar intensity ratio range as compared to GSH-GST-7E15N (BAB-IC, 76 %)
complex formation. The GST-free elution sample (BAE, 79 %) has a comparable intensity ratio to the
labeled BAB-IC sample, and BAE shows the efficiency of the complex formation (GSH-GST-7E15N) before
enzyme cleavage. In addition, enzyme cleavage of the GSH-GST-7E15Q complex gives a low percent
intensity ratio for the GST-free moiety. Three possibilities to the lower GST free percent intensity are:
the low GSH concentration present in the elution buffer, the pH adjustment of the elution buffer, and
the thrombin concentration for enzyme cleavage. GST-7E15N and GST-7E15Q, treated with the lysis
buffer C, illustrate similar solubility/insoluble intensity ratio as compared to the same protein variants
treated with the lysis buffer A.
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3.3.2.2 The denatured-refolded influence on the GS-4B purification of ProCA1 charged
variants
The insoluble portion of 7E15E, 7E15N, and 7E15Q are treated through a refolding method, and
the binding capability of the refolded sample is passed through the GS-4 beads. The results are compiled
in the form of each sample lane intensity displayed on the 15 % SDS-PAGE (Figure 3.15). All three GSTProCA1 charged variants demonstrate similar weak binding capability to the glutathione-coated beads.
Lane 1 to 4 demonstrate the successful refolding of GST-tag 7E15N and 7E15Q based on the consistency
in the protein band intensity at 37.2 KDa. In following, GST-tag 7E15N and 7E15Q interestingly has
similar unbinding to the column by comparing lane 6 and 7 similar band intensity. The quantified
intensity ratio further supports these visual observations of the SDS-PAGE results (Figure 3.12).
Evidently, there is a low binding interaction between the glutathione reduced form and the GST-7E15N
and GST-7E15Q as indicated by the light protein band in lane 8 and 9. In the contrary of GST-tag 7E15N
and 7E15Q, GST-tag 7E15E demonstrates a low solubility after treatment with 8 M urea for one hour.
The clear difference in protein band intensity between the supernatant in lane 1 and the inclusion body
in lane 2 supports these observations for GST-tag 7E15E. All refolded GST-tag proteins that are
recovered at the soluble state demonstrate a low binding activity towards the reduced glutathione
present on the sepharose beads in the gravity column. Some factors to consider are 1) the expression
yield in terms of band intensity for the proteins prior to cell lysis, 2) the state of the glutathione coated
beads in the column, 3) the refolded GST-ProCA enzymatic activity, and 4) the pH condition of the
column. The overall yield obtained after purification is depending of the initial yield gathered during
overexpression of the GST-tagged ProCA1s. The concentration of the salt, ionic detergent, denaturant,
and pH play an important role in the case of refolding these GST-tagged ProCA1s.
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3.3.2.3 ProCA1 charged variants isolated by the FPLC cation exchanger SP-column
The concentration of each protein elution fractions are monitored through the UV-Vis
spectrophotometer and then prepared for further isolation through the FPLC SP - column system. Each
protein sample is adjusted to a low pH (4.00 - 3.00) for elution based on a pH gradient program. The
protein at this specific acidic pH is expected to bind to In addition, the protein’s original binding pocket
holds acidic residues (aspartic and glutamic acid). The side chains of these residues are protonated due
to the acidic condition of the sample and for an effective binding to the SP- cation exchanger column. All
ProCA1 charged variants elute out at pH: 7.20 to pH: 7.40 (Figure 3.16). The desired fractions that
demonstrate the highest mAU in that pH range are collected and then passed though an ultrafiltration
system. Table 3.1 summarized the protein final concentration and yield is determined based on the UVVis spectra and these samples are used for the conformational analysis.
3.3.2.4 Comparing the yield (mg/L) after the GS-4B purification of ProCA1 charged variants
The purpose of compiling the UV-Vis absorbance ratio is to compare the level of nucleotide
presence in correspondence to lysis buffer. Second, the final concentration (μM) and the yield (mg/L)
based on the elution concentration are compared based on the lysis buffer system. A detail analysis on
which lysis buffer Best contributes for high protein yield is analyzed for each ProCA1 charged variant
(Table 3.1). Furthermore, the concentration obtained for the refolding attempt of the insoluble portion
of GST-tag variants after cell lysing is compared as well with the previous lysis buffer system. 7E15E (9
mg/L) and 7E15N (4 mg/L) show highest yield in lysis buffer B, while 7E15Q (10 mg/L) has highest yield in
buffer A. ProCA1 (29 mg/L) demonstrates high yield based on the lysozyme content in the buffer C. A
small yield is obtained for 7E15E (2 mg/L), 7E15N (1 mg/L), and 7E15Q (0.47 mg/L) after refolding the
GST-tag protein from the inclusion body in buffer B. As a result, a small percent amount of the proteins
are recovered back into the soluble state. The intensity ratio for the samples taken during the refolding
of the GST-tag proteins from the inclusion body is supported in Figure 3.15.
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Figure 3.14 The GST-tag purification of ProCA1, CD2.7E15E, CD2.7E15N, and CD2.7E15Q with
modifications in the cell lysis buffer.
The following are the 15% SDS-PAGE samples taken for each ProCA1 charged variant: a) the
conventional cell lysis buffer (1% N-Lauralsarcosyl, 1 mM EDTA, 0.50 mM PMSF), b) the modified cell
lysis buffer (1 % N-lauralsarcosyl, 5 mM EDTA, 6.7 mM PMSF, 10 mM DTT, 0.05 % Triton-X 100), and c)
buffer A condition with lysozyme (1 mg per 1 liter cell cultured) for ia) CD2.7E15E, ib) ProCA1, ii)
CD2.7E15N, and ii) CD2.7E15Q.
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Figure 3.15 A summary of the intensity ratio for each sample from the GST-tag purification of ib) ProCA1, ia) 7E15E, ii) 7E15N, and iii) 7E15Q
with the indicated lysis buffer conditions.
Each columns represent the a) lysis buffer A, b) lysis buffer B, and lysis buffer C with the protein band intensity ratio for each sample collected
during the GS-4B purification system.
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Figure 3.16 The GST-tag refolding purification of CD2.7E15E, CD2.7E15N, and CD2.7E15Q
There is a summary of the intensity ratio for each sample from the GST-tag refolding purification of a)
CD2.7E15E, b) CD2.7E15N, and c) CD2.7E15Q.
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Figure 3.17 An example of the FPLC chromatograph for CD2.7E15Q (pH: 3.80) through the pH gradient in the SP column
A low pH range (~ 3 to 4) is adjusted to isolate our 7E15Q from thrombin (< ~1 mg/mL), reducing reagent (DTT), and detergents (1 % sarcosyl
& Triton X-100). The above chromatograph indicates the purity of the protein sample after the GS-4B column purification, and the fraction
sample collected shows one distinct protein band on the 15 % SDS-PAGE affirming the stability, no degradation, and purity level of the
sample protein after isolation from thrombin.
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Table 3.1 A summary of the UV-Vis absorbance ratio and yield (mg/ 1 L culture) for each eluted or
concentrated samples from the GST-tag and refolding method of the charged ProCA1 variants.
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3.3.2.5 The effect of lysis buffer conditions on the purification of GST-tagged ProCA1s targeted
This Section consists of the GST-tagged ProCA1.affi targeted variants that are purified
within a set of lysis buffers. Each buffer as mentioned earlier is tested to see which one promotes
highest solubility to insolubility intensity ratio after cell lysis. In addition, the binding efficiency between
the GST-tag proteins and the GSH coated sepharose beads are observed during the purification step.
Each lane on the 15 % SDS-PAGE represents the samples taken during the GS-4B column purification
step. The specific bands displayed in a red box are quantified using the Image J software. The two parts
to the purification results of ProCA1.affi342 and ProCA1.affi1907 are: a) the soluble portion or SN of the
protein that is passed through the GS-4B column, b) the insoluble form of the protein that is collected
for possible refolding through the use of the lysis buffer B. These results are demonstrated on the 15 %
SDS-PAGE (Figure 3.17, 3.19). Initially, the first part into obtaining the eluted ProCA1.affibodies
demonstrate different outcomes for binding capability and elution output when comparing the buffer
lysis conditions. These results are analyzed further in a quantitative manner for both part A and B.
Each cultured cell pellets that contain GST-ProCA1.affi342 or GST-ProCA1.affi1907 is purified in
subsequent different lysis buffers. The results are discussed through detailed analysis of the measured
intensity ratios for each of these two variants based on the individual gel band results with
correspondence to the used lysis buffer. Consistency with the protein extraction from the host cell is
observed in the intensity ratio for GST-ProCA1.affi342 between the SN and IB. So there is an equal
amount of the protein present as soluble and insoluble form after cell lyses when using buffer A. The
same case is observed when using buffer B. Increasing the chelator, EDTA, concentration (mM) and
adding detergent does not increase the folding of the GST-protein complex into the soluble form after
cell lyses for ProCA1.affi342. In the case of using buffer C, more inclusion body is observed when adding
lysozyme prior to cell lyses with sonication/cell disruption. This particular condition may not necessarily
contribute to high inclusion body; other factors such as the expression conditions may have an indirect
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impact on this outcome. Following this phenomenon, there is less GSH-GST-ProCA1.affi342 present
inside the GS-4B column. For the case of ProCA1.affi1907 targeted to EGFR, insoluble portion is lower in
percent intensity during the usage of buffer lysis A (59 %) and C (48 %), while there is no significant
change in the insolubility of the protein when using buffer lysis B. There is a large amount of GSH-GSTProCA1.affi.EGFR after using the lysis buffer B (61 %) and C (85 %) while there is a low GSH-GST-protein
formation (28 %) in the column after using cell lysis buffer A.
3.3.2.6 The denatured-refolded influence on the GS-4B purification of targeted ProCA1s
Part B of the purification results involves the analysis of the refolded inclusion body collected
during the use of the lysis buffer B for both GST-ProCA1.affi.HER2: 342 and GST-ProCA1.affi.EGFR. The
supernatant that is recycled after the washing step during the initial GS-4B column purification is
refolded alongside the inclusion body and the results are compared in the 15 % SDS-PAGE (Figure 3.19)
and the protein bands’ intensity ratio (Figure 3.20). The assumption is that the non-bond GST protein
may be inactive or have some misfolding of the thiol group although it is present in the soluble form.
There is darker band intensity for the refolded GST-ProCA1.affis from the inclusion body form compared
to the refolding step of the recycled washout or supernatant. These observations are taken from a
qualitative into a quantitative approach as the intensity ratios are measured for indication of the
percent density of the protein of interest present in each sample (Figure 3.19).

GST-

ProCA1.affi.HER2:342 decreases in density during the refolding step and only 43 % intensity ratio is
passed through the GS-4B column as compared to the referenced SN treated in 8 M urea for one hour
while GST-ProCA1.affi.EGFR has a constant intensity ratio during the refolding process of the inclusion
body. The increased solubility is most prominent for GST-ProCA1.affi1097 during inclusion body
refolding. For the case of refolding the recycled washout or supernatant, GST-ProCA1.affi.HER2 and
ProCA1.affi.EGFR (83 %) both demonstrate a consistence in percent intensity based on the final sample
(SN, 10 mM Tris) obtained prior to GS-4B column purification. As a result, ProCA1.affi.HER2:342 (55 %)
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and ProCA1.affi1907 (47 %) showed a 50 % staining recovery in the elution sample. The yield is obtained
after the purification and then compared for both protein variants. The goal is to refold the insoluble
form into a soluble form then treat the refolded supernatants through the GS-4B column for further
purification. This is the process that is applied for essential back-up recovery of additional protein as
gaged by its ability to bind to the column and to increase the yield after purification. The compared yield
is determined using the UV-Vis absorbance maxima and final concentrated volume of the purified
samples (Table 3.2).
3.3.2.7 Comparing the yield (mg/L) after the GS-4B purification of targeted ProCA1s
The protein sample is isolated and a spectrum (Figure 3.18) with the specified fraction peak is
collected based on the SDS-PAGE. Table 3.2 summarizes the yield measured for each ProCA1.affi variant
with the corresponding final volume (mL). The GST-ProCA1.affi.HER2 and GST-ProCA1.affi1907
demonstrate drastically different elution yield. In the case of refolding, it is evident that GSTProCA1.affi.HER2: 342 (0.05 mg/L, 1 mg/L) have a lower yield compared to GST-ProCA1.affi.EGFR (7
mg/L, 4 mg/L) after the denatured-refolding from the supernatant or inclusion body sample,
respectively. This observation suggests that GST-ProCA1.affi1907 is most susceptible to the refolding
process and increase capability of the GST moiety to catalyze the reduced glutathione on the beads for
complex formation with GSH when passed through the GS-4B column.
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Figure 3.18 The GST-tag purification of ProCA1.affi342 and ProCA1.affi1907 with modifications in the cell lysis buffer.
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Figure 3.19 A summary of the intensity ratio for each sample from the GST-fused purification of ProCA1.affi342 and ProCA1.affi1907 with
modifications in the cell lysis buffer.

95

Figure 3.20 The GST-tag refolding purification of ProCA1.affi342 and ProCA1.affi1907.
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Figure 3.21 A summary of the intensity ratio for each sample from the GST-tag refolding purification of ProCA1.affi342 and ProCA1.affi1907.
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Figure 3.22 The FPLC chromatograph of ProCA1.affi1907 through the Q column based on a salt-gradient.
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Table 3.2 A summary of the UV-Vis absorbance ratio and yield (mg/L) for each eluted or concentrated
samples from the GST-tag and refolding method of the targeted ProCA1 variants.
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3.4 Conclusion and Future Work
This Chapter involved expressing and purifying the various ProCA1 variants that are charged
and/or targeted. The most effective approach used for optimizing the production of these proteins is
through a series of troubleshooting the expression and purification in different set conditions. This
Chapter takes part in two series: a) the optimization of expressed GST-tagged ProCA1 variants, and b)
the optimization of purified GST-tagged ProCA1 variants through a gravity GS-4B column. The initial step
to producing the recombinant proteins is via a fed-batch/bench work expression system. This task takes
about a week for completion and the cultured cells that contain the expressed protein of interest is the
end result prior to the purification step. The essential outcome from the expression and purification are
discussed further into two parts. Part A discussed the summary obtained from the optimization of the
small and large-scale expression system for GST-tag ProCA1 variants, while part B focuses on the
summarized results from the gravity GS-4B column purification.
3.4.1 Summary of the small and large-scale expression for all ProCA1 variants
The optimal conditions are summarized with reference to the fixed conditions as listed in Table
3.3. In the small-scale expression system, all charged variants cultured in the smaller LB culture volume
exhibit no significant difference in the expression level of the GST-tagged proteins with the varied cell
strains. The three sets of fixed parameters in the large-scale expression are between 1) E.coli cell strain,
2) post-induction temperature, and 3) inducer concentration (i.e. IPTG). All the GST-tagged proteins are
expressed depending on these sets of fixed conditions. During expression in the same E.coli cell strain
and post induction temperature and time, all ProCA1 variants demonstrate similar culture growth levels
with 0.20 mM IPTG. Similarly, the affibody-targeted variants show the same expression level with 0.35
mM IPTG during treatment of the same E.coli strain and temperature conditions. ProCA1 is the set
control for the expression and it demonstrates a similar expression behavior as the targeted variants for
expression at a high temperature. During a fixed temperature/cell strain: a successful optimizing
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condition is indicated for the high expression level of GST-tagged 7E15E, 7E15N, 7E15Q (0.20 mM IPTG
at 25 °C in BL21 (DE3), GST-tag ProCA1.affi342 and ProCA1.affi 1907 (0.35 mM IPTG at 37 C in BL21
(DE3), following ProCA1 (0.30 mM IPTG, at 37 °C in BL21 (DE3). At a fixed IPTG /temp, successful high
expression level is present between BL21 (DE3) pLySs and BL21 (DE3) for GST-tag ProCA1 affibodies. At a
fixed IPTG /cell strain, successful high expression level is present at 25°C and 37°C in BL21 (DE3) pLySs/
BL21 (DE3) for GST-tag ProCA1 affibodies, and GST-tag 7E15E, and 7E15N. Results suggest that at low
temp with a longer cultivation time for the 3 charged variant proteins’ (7E15E, 7E15N, and 7E15Q)
expression level is most favorable while a shorter cultivation time at high temp is suiTable for the
targeted ProCA1 variants (ProCA1.affi342 & ProCA1.affi1907). As future plan, we aim to modify the trials
further for expression on the small scale with a set control for IPTG, or temperature, and correlate those
findings with the current large-scale results.
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Table 3.3 The summary of the small-scale and large-scale expression of GST-tag ProCA1 variants.
The small-scale expression represented on the left hand panel of the Table refers to the effect of the host cell strain while the large-scale
expression represented on the right hand panel refers to the host cell strain (green), temperature (purple), and IPTG (yellow) concentration.
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3.4.2 The summarized GST-tag purification of charged and/or targeted, ProCA1 variants
The purification of the ProCA1 variants is optimized though troubleshooting in the three sets of
lysis buffer conditions. The breaking of the bacteria cell wall is essential for excretion of the recombinant
protein of interest, and in doing so; the protein is exposed to harmful agents present in the lysate after
cell lysis. In addition, the viscosity of the lysate sample, the solubility, and bioactive form of the GSTProCA1 variants is important to proceed into the GS-4B column. In pointing out these key factors, the
essential idea for optimizing this purification system is to modify the lysis buffer for promoting an
increase in the solubility of the tag-protein for potential higher recovery into the soluble state after cell
lysis. I hypothesize that a high ProCA1 variants ratio are folded partially due to the method of cell lysing;
as a result they are present in the soluble form and a potential higher yield is obtained after the GS-4B
column purification. Treating the extracted protein with different cell lysis buffer conditions tested this
hypothesis. The overall results convey otherwise that the lysis buffer condition has a small impact on the
overall protein folding during protein extraction from the host cell and the final yield measured after GS4B column purification. The change in the components within the lysis buffer posed some change in the
solubility and binding efficiency of the GST-ProCA1 variants but these results varied with the particular
ProCA1 variant. The -5 and -4 charged variants are compared in terms of the soluble/insoluble and
unbound/bound form during GS-4B column purification.
It is more prominent that -5 charged variants demonstrate a high percent intensity ratio of the
soluble and bound form (lysis buffer A and lysis buffer C). There was no significant change between the
soluble and insoluble form based on the similar intensity ratio exhibited by 7E15E (lysis buffer B). In
addition 7E15E demonstrates a high percent intensity of the unbound form (99 %) compared to the
bound form (54 %) during the purification. The measured yield (lysis buffer B, 9 mg/L) is 3 fold higher
than the yield obtained after treatment of the lysis buffer A (3 mg/L). Based on these conclusions, the
lysis buffer A promotes a higher soluble/insoluble ratio for GST-7E15E without the added DTT, high
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EGTA concentration, triton x-100, and lysozyme. 7E15N and 7E15Q are -4 charged variants and their
results are compared to the -5 charged variants.
There is no change in the soluble to insoluble ratio for 7E15N in the lysis buffer A and C
(1.08,1.00), respectively, while buffer B has a lower ratio indicating an increase in the inclusion body
formation. The high increased soluble/insoluble ratio is present in 7E15E that is treated with lysis buffer
A, 7E15N (lysis buffer A, C, and D), 7E15Q (lysis buffer A, C, D). For the targeted protein variants,
ProCA1.affi342 demonstrates high intensity ratio in lysate buffer A, B, and D for the soluble/insoluble
ratio. ProCA1.affi1907 shows high intensity ratio in lysate buffer A and C. The ultimate goal is to obtain
the highest ratio of the protein of interest in the supernatant and for this protein to demonstrate high
binding interaction inside the column. This can be detected by the increase ratio values for SN/IB and
BAB-IC/BAB-OC.
The soluble form is achieved through the use of lysis buffer A, C, and D, where the conditions in
the buffer successfully demonstrate the high intensity ratio of soluble/insoluble form of 7E15E, ProCA1,
7E15N and 7E15Q. In the case of the targeted protein buffer A, B, D demonstrates high soluble/insoluble
ratio of ProCA1.affi342, while buffer A and C demonstrate highest soluble/insoluble ratio of
ProCA1.affi1097. Not only is the increased solubility of importance in this analysis, but also achieving a
high binding/unbinding form inside the column is important for potential higher output of the protein of
interest after enzymatic cleavage with thrombin. The increase in bound/unbound form is present in the
following buffers with the corresponding protein: 7E15E (A), 7E15N (C), 7E15Q (C), ProCA1.affi342 (A),
ProCA1.affi1907 (C). In terms of the yield there is no significant correlation demonstrated with the
highest intensity for both SN/IB and BAB-IC/BAB-OC. These results are essentially preliminary and
suggest that further analysis is needed for effective conclusions to be made.
The current conclusion that can be made based on these preliminary results is that modifying
the current lysate buffer conditions in A into lysate buffer B is essential for obtaining a high yield as
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demonstrated for 7E15E (9 mg/L) and 7E15N (4 mg/L). In following, we must consider the discrepancy to
the data obtained because each cultured pellets come from varying expression conditions as 7E15Q,
ProCA1.affi342, and ProCA1.affi1907 demonstrate a highest yield in different lysate buffer conditions, A
(10 mg/L), C (5 mg/L), and D (7 mg/L). Thus, further analysis into modifying the conditions such as
increasing the percent concentration of the triton X-100 detergent and verifying the pH of the buffer
throughout the cell lysis process are some essential criteria to consider for future experimental plans.
Further analysis is needed for accurate interpretation of the data collected because these results are a
summary of single trials. As future work, the experiments will be scaled-down for ease of executing the
experiment in triplicates for each corresponding lysis buffer condition. The end result will be gathered
data that is easily re-producible, more effective and reliable.
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Figure 3.23 The summary of the GS-4B purification of each ProCA1 variants; charged and targeted.
Each protein variant is indicated with their intensity ratio of the bound/unbound form (grey/yellow)
and the soluble/insoluble form (blue/purple) in a) the GS-4B purification and b) refolding of IB. c) Each
yield is indicated with their corresponding protein variant and lysis buffer condition while the
summarized yield (mg/L) is measured using the UV-Vis absorbance maximum at 280 nm for GS-4B
purification and d) refolding of GST-tagged ProCA1s.
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4. CONFORMATIONAL ANALYSIS, METAL BINDING, AND RELAXIVITY PROPERTIES OF THE
ENGINEERED PROCA1S
4.1 Introduction
Chapter 4 focuses on the detailed structural conformation, metal binding and relaxation analysis
of the expressed and purified ProCA1 variants, both targeted and charged. These analyses are important
for the prospective clinical application. In following, ProCA1 variants are derived from the CD2.D1, or
CD2.WT; that is an adhesion protein with a secondary β-sheet structural conformation (Figure 1.3).
There are several spectroscopic techniques such as NMR, CD, and fluorescence that can be used to
investigate the conformational changes of the ProCA1 variants. Specifically, tryptophan fluorescence
emission and far ultraviolet (UV) CD spectroscopy are used among these applications. The secondary
structure of the designed contrast agents after purification is investigated using far UV CD.
Conformational change upon metal binding with the physiological (such as Ca2+, Mg2+, K2+, and Zn2+) and
lanthanide metals ( e.g. La3+,Tb3+, and Gd3+) can also be examined by this method.
The ProCA1 variants and its wild type have two distinct tryptophan residues (i.e. Trp 7 and Trp
32). Trp 32 is buried within the hydrophobic core and Trp 7 is exposed on the hydrophilic surface of rat
CD2.D1. This known structural characteristic is used to monitor the tertiary conformational analysis of
the ProCA1 variants after the purification method. The tryptophan fluorescence emission signal is used
to detect the folding of the variants with indication of the blue shift of the fluorescence maximum at the
specified wavelength (350 nm) due to the buried tryptophan. The well-folded CD2.WT protein has a
short wavelength emission maximum at ~ 325 nm where a blue shift occurs from the standard free Ltryptophan emission at 350 nm. The ProCA1 variants have a metal binding pocket and specific
competition assays are developed for the analysis of metal binding interaction of the ProCA1 variants to
the lanthanide metals (Tb3+, Gd3+). Commercially available dyes are used as probes for detection of the
binding affinity for lanthanide metals of the engineered binding proteins. The determined dissociation
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constant can indicate whether the engineered binding pocket is functioning properly in terms of the
stability of the metal-protein complex. Accordingly, the goals of this Chapter are to examine
conformational properties, determine the metal binding affinity, and the relaxivity values of protein
variants after purification.
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4.2 Methods
4.2.1 Intrinsic tryptophan fluorescence emission spectra
The secondary conformation of all ProCA1 variants was studied through the measurement of
the tryptophan fluorescence emission. Measuring the tryptophan fluorescence emission signal will
determine whether the purified protein holds a compact globular structure. The emission intensity peak
between 300 - 350 nm demonstrated the folding of this protein. The hydrophobic core of the protein is
intact if a blue shift is demonstrated at a lower wavelength (~325 nm). This result assured that the
protein holds a sTable secondary structure. The parameters involved exciting at 280 nm and measuring
the emission at a range of 300 nm to 500 nm.
4.2.2 Far Ultraviolet Circular Dichroism
The CD experiment was measured using Jasco-810 spectropolarimeter.

All samples were

prepared at a set concentration with a stock volume (300 uL- 1 mL) then placed in the 1 mm path length
quartz cuvette. Spectra were measured from a starting wavelength at 260 nm and a final at 190 nm with
with an accumulation of 5 or 15. To determine the percent composition of the secondary structure of
the experimental spectra, each protein spectrum were fitted through a set of analysis programs (e.g.
SELCON3, CONTINLL, CDSSTR, K2D) provided by DICHROWEB server [65-66]. The best graphical output
correlates with the percent beta strand and helix results from the protein data bank (Pdb) file of CD2.
WT, (1hng). All exported raw data were converted using Equation 4-1 from mdeg to mean residue
ellipticity (M.R.E.) as a function of the wavelength (nm). The best fitting was averaged in terms of the
percentage in helix, strand, and turns for the secondary structure analysis determined by each program.
CD2.WT is used as a control (Figure 4.5).
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Equation 4-1
, where l is the path length, C is the [ProCA], and n is the residue number of the ProCA.

4.2.3 ProCA1 variants binding to Tb3+ through an NTA-Tb3+ buffer system
Metal binding capability of the protein of interest was analyzed through a series of metal
binding assays through the use of a spectrophotometer (photon technology international, (PTI) FEliX32
software) but the initial determination of the appropriate dynamic range for free terbium (Tb3+) is
essential for the correct binding affinity between the ProCA1 variants and the lanthanide metal (Figure
4.7). Once the dynamic range of free Tb3+ is established for ProCA1, the metal binding behavior towards
Tb3+ is examined for each ProCA1 variants at the exception of ProCA1.affi342 due to the low stock
concentration available. A buffer system involving nitrilotriacedic acid (NTA) chelating agent is used to
compete with ProCA1-Tb3+ complex. Decreased fluorescence intensity occurs during this buffer titration
system. The dissociation constant of free terbium to ProCA1 variant is determined based on the
fractional change or relative fluorescence intensity, Δf, as a function of the log base concentration of
free Tb3+ (M) (Equation 4-2).
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Equation 4-2

Equation 4-3

We use the buffer system because it assures that a reasonable dissociation constant can be
determined after the data processing through elimination of background noise. There are two sets of
buffer conditions used for the NTA-Tb3+ buffer system. Buffer A had 20 mM PIPES, 100 mM KCl, at pH:
6.8, with 500 μM NTA, 500 μM Tb3+ and 20 μM ProCA1 variants. Buffer B is the same sample as buffer A
with the exception of no protein present in solution. Buffer B is an experimental control where no
distinct change in fluorescence intensity is observed during each titration points. This assures that the
actual decrease in fractional change is due in part to the release of free Tb3+ in solution as ProCA1-Tb3+
complex formation decreases. The 100 mM NTA stock is titrated into both buffer systems
simultaneously with the varied dilution factors for each titration points. Fluorescence emission was
measured in the light region, and thus a range from 200 nm to 600 nm was expected for the
fluorescence spectra. Both sample buffer A and B was scanned at 280 nm excitation and 500 nm to 600
nm emissions. A decrease in fluorescence intensity is observed at 545 nm that is the emission of Tb 3+
total present in the sample. Tb3+ free in the sample is calculated based on the difference between Tb3+
total and Tb3+ -NTA total in sample buffer A (Equation 4-6). The Tb-NTA total in the sample during each
titration points is represented as the fractional change during the titration process (Equation 4-5). NTA
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has a dissociation constant (Kd) of 10-12 M for Tb3+ and the Kd of ProCA1-Tb3+ complex has been
previously determined to be at 10-12 M. So the decrease in fluorescence intensity is normalized as the
fractional change or relative fluorescence intensity (Equation 4-3) and plotted against the log based
value of the calculated free Tb3+. The determined dissociation constant is represented as m1 or the IC50
based on the hill Equation for the curve fit of the data points (Equation 4-5). Please refer to Dr.
Shenghui Xue’s dissertation for further details of this procedure.
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Equation 4-4

Equation 4-5

Equation 4-6
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4.2.4 FLuo-5N competition assay through fluorescence spectroscopy
Another competition assay used for determination of the dissociation constant of ProCA1
variants to Gd3+ is the use of Fluo-5N dye, where the ProCA1 variants are competing with the dye to bind
to Gd3+ in a specified buffer environment with 100 mM KCl at low pH. We devised a competition assay
with the use of a commercially available dye named FLuo-5N [67]. The dye acts as a chelator for Gd3+,
and protein of interest is titrated into the buffer system containing the dye-Gd3+ complex. Through
titration, the intensity decreases as the ProCA1 variants compete out the Gd3+ from the dye. Essentially,
the relative fluorescence intensity is plotted as a function of the increased protein concentration
throughout the titration process. The curve fit for the processed data points was executed through
Kaleidagraph software using Equation 4-7 based on a 1: 1 binding mode. The apparent Kd is initially
measured and represents the combined intermediate complex form between Fluo5N----Gd3+ - ProCA1.
The determined kapp is m2 and all known variables needed for determining the actual kd2 is calculated
through Equation 4-8. The dissociation constant (Kd2) for Gd3+ binding to ProCA1.affi1907 or CD2.7E15Q
is calculated based on the known kd1 of the dye to Gd3+ and the apparent dissociation constant (Kapp)
from the curve fit using Equation 4-7. Further details of this method can be found in Natalie White’s
thesis.

Equation 4-7

Equation 4-8
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4.2.5 Relaxivity measurement
The T1 and T2 relaxation time delay were measured using the 60 MHz relaxometer (minispec
ProFiler, Bruker Corporation). The relaxation rate is determined based on the following formula:

Equation 4-9
; where [Gd3+] symbolizes the gadolinium metal concentration and [Contrast Agent] represents
the measured T1 and T2 values of the buffer only (i.e. 10 mM HEPES at pH: 7.0).
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Figure 4.1 The schematic representation of NTA-Tb3+ buffer system.
a) The NTA sample is added subsequently (μL increments) into buffer A and B. The NTA chelator has a
Kd: 10-12 M towards Tb3+. As a result, the complex form of the protein-metal concentration decreases
in buffer A while NTA-metal complex increases in concentration in both buffer A and B. Both sample
buffer A and B is excited at a fixed 282 nm while the maxima intensity is emitted at 545 nm. b) The
mechanism in buffer A is demonstrated as excess NTA causes a decrease in the Tb 3+ ‘s fluorescence
intensity.
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Figure 4.2 The schematic representation of FLuo-5N competition assay.
a) The ProCA1 sample is added subsequently (μL increments) into buffer A. As a result the complex
form of protein-metal concentration increases while Fluo-5N-metal complex decreases in
concentration in buffer A. b) The excitation is fixed at 494 nm while the maxima intensity is emitted
at 515 nm for the mechanism that occurs in buffer A during the measurements of Fluo-5N dye’s
fluorescence intensity.
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4.3 Results and Discussion
4.3.1 The conformational analysis of CD2 mutants using Far UV-CD
After expressing and purifying the protein of interest discussed in Chapters 2 and 3, specified
techniques are applied for further structure and functional analysis of the purified sample of that
protein. Specifically, in this Section, the structural characteristics of the ProCA1 variants are analyzed
through far ultraviolet-visible circular dichroism and tryptophan fluorescence emission spectra.
The 7E15Q (pET-20b, tag-less) demonstrates a different CD spectra compared to 7E15Q (pGEX2T , GST-tag) (Figure 4.3 a). The two proteins come from different purification methods, and the results
are surprisingly different in terms of minima values. 7E15Q expressed as a fusion with GST demonstrates
similar spectra to the CD2.WT also expressed as a fusion with GST. This phenomenon suggests that the
conformation is different for ProCA1 variants purified through a tag system compared to tag-less
purification. There are some factors to consider for a plausible explanation of this occurrence, which are
as follows: a) the purification method, b) the protein concentration, c) purity of the buffer system and or
the purity of the protein samples. As mentioned previously, the same protein may maintain a different
folding conformation suggesting the drastic change in CD spectra through different purification
methods.
4.3.1.1 Metal binding influence on the secondary structure of 7E15Q and

ProCA1.affi1907

The example of the CD spectra overlay demonstrates the conformational change observed
during exposure of varying metal ions (Figure 4.4). The physiological metal does not change the
secondary structure of 7E15Q (Figure 4.4 a). The holo and apo form of 7E15Q have no change in the
secondary structure when comparing the spectra overlay. To confirm these findings, a CD curve fit of the
raw data is fitted through the use of an analysis program named CONTINLL. These results are
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summarized in Table 4.1. CD2 WT ( x-ray) refers to the pdb file results of the percent secondary
conformation, which is 1 % helix and 53 % strand. The results indicate that 7E15Q (pET20b, tag-less
method) as apo form is at 99 % helix while the holo form with Ca2+ has 2% helix and 49 % strand
conformation.
There is drastic change in the minima at ~ 210 nm -215 nm, compared to the minima at ~222 nm
in the presence of both lanthanide and physiological metals for ProCA1.affi1907 (Figure 4.4 b). The
highest minima at the 215 nm wavelengths indicate conformational change in the ProCA1.affi1907
secondary structure with Gd3+ and Mg2+. There is a similar decrease in ellipticity for ProCA1.affi1907 in
the presence of Zn2+ and Ca2+. The drastic change in ellipticity minima is due in part to the high metal
concentration and low pH 6.8 value. Metals dissociate easily in water in the presence of low pH, and this
acidic environment is considered during the analysis of the secondary structure of ProCA1.affi1907. The
radius size of the particular metal ion is essential for appropriate comparison as well as the solubility in
the presence of protein solution. Only terbium ion demonstrated precipitation during the presence of
the protein sample, which explains the small change in ellipticity compared to the other metal ions. One
consideration is the determination of the solubility product constant during sample preparation of the
stock metal ions, in addition to a smaller protein to metal ion concentration ratio of 1:2 instead of the
1:200 ratio for a more distinct change in ellipticity minimum.
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Figure 4.3 Comparing the secondary structure of CD2.WT versus ProCA1 variants versus
ProCA1.affi1907 through Far UV-CD.
Each CD spectrum represents an average of 15 CD scans placed on a) the prepared samples of 50 μM
7E15Q, 20 mM EGTA and the expressed 7E15Q/pGEX-2T demonstrate similar minima to
CD2.WT/pGEX-2T at ~ 216 nm representative of the secondary β-sheet conformation in a 1 mm cell at
a far UV wavelength (200- 260 nm). b) The far ultraviolet CD spectra overlay of ProCA1.affi1907-2 mM
EGTA demonstrates minima at a range between 200 nm to 230 nm with CD2.WT as a control.
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Figure 4.4 The effect of the metal ions on the secondary structure of a) 7E15Q and b) ProCA1.affi1907.
a) There is a slight change in mean residue ellipticity (M.R.E., deg*cm 2/dmol) values between the
overlaid spectra, which indicates no significant β-sheet conformational change imposed by the
protein-calcium solution. b) Comparing the M.R.E. value for ProCA1.affi1907 (10 μM) based on the
presence of the varying metals (2 mM), which is 1:200 ratio based on the protein to metal
concentration.

Table 4.1 A summary of the percent secondary structure construct of CD2.WT, 7E15Q and
ProCA1.affi1907 targeted to EGFR based on the far UV CD spectra.
Each protein sample has the corresponding percent helix, strand, turns, and unordered. These values
are generated from CONTINLL analysis program. The determined percent values that correlate to the
known values provided by the pdb file of CD2.WT (X-ray) are highlighted in yellow.
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4.3.2 Intrinsic tryptophan emission of 7E15Q and ProCA1.affi342 targeted to HER2/neu
The tryptophan fluorescence emission demonstrates a small blue shift present compared to the
free-tryptophan emission spectra for ProCA1.affi1907 (Figure 4.6 d). This phenomenon demonstrates
that the sample has a partially exposed hydrophobic core in the non-denatured environment. In
addition, there is a similar maxima emission to the free L-tryptophan emission spectrum at ~ 352 nm for
ProCA1.affi1907 exposed in 8 M urea and 6 M guanidine hydrochloride. Although the UV-Vis spectra
indicate the similar maxima absorbance at 280 nm, there is no indication that the ProCA1.affi1907 holds
a compact hydrophobic core based on the tryptophan emission spectra at ~ 348 nm.
The fluorescence tryptophan emission is similar for ProCA1 (pET-20b tag-less) and ProCA1
(pGEX-2T, GST-tag) (Figure 4.6 a,b). These results suggest that the tertiary conformation of the protein is
intact due to the blue shift phenomenon. The shift at the shorter wavelength (~325 nm) demonstrates a
sTable tertiary conformation representative of the buried tryptophan residue in the hydrophobic core.
Some samples are treated with denaturant and used as a control and compared with the sample in the
non-denatured environment. This technique is applied to ensure that a well-folded protein is present in
the purified solution. Guanidine hydrochloride or urea at high concentrations causes the 350 nm
tryptophan emission similar to the L-Trp free that is used as a control. Further tests are considered for
analysis of the CD spectra based on the different methods of purification applied to the protein of
interest. One-dimensional NMR can be considered as a spectroscopic technique for further work on the
structural conformational analysis of these ProCA1 variants.
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Figure 4.5 shows the intrinsic tryptophan emission spectra of ProCA1 and ProCA1.affi342 compared
with the free Trp in 10 mM HEPES, pH 7.0.
The fluorescence Intensity spectra overlay for tryptophan emission at ~325 nm of the buried Trp 32 in
a) ProCA1/pET-20b and b) pGEX-2T demonstrates a blue shift compared to L-Trp free at 350 nm.
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4.3.3 NTA-Tb3+ buffer system fluorescence titration
The charged variants are analyzed through a two-set buffer system where NTA is used as the
chelator that competes with ProCA1-Tb3+ complex for binding with the lanthanide metal ion. This
chelator possesses a smaller dissociation constant (10-12 M) for Tb3+ compared to ProCA1 variants.
Ideally, the binding affinity of the ProCA1 variants toward the lanthanide ion should be small at the
nano- to pico-molar range. After analyzing the binding capability of the ProCA1 variants with saturated
terbium concentration at a wide range (Figure 4.7), the dynamic range for the free terbium
concentration is determined within 300 μM to 1000 μM of the total terbium concentration for effective
dissociation constant determination using the Hill Equation. This reasoning is the basic principle behind
the determination of the specified free terbium present in solution, which is in the specific dynamic
concentration range of 10-11 M and 10-13 M during a curve fitting.
CD2.7E15N and CD2.7E15Q have an assumed -4 net binding pocket charge based on the two
aspartic acid and two glutamic acid residues in their designed metal binding site. These mutations differ
at one site of the binding pocket, and the metal binding capability for Tb3+ ion is analyzed through a
devised competition assay with the use of a fluorometer. Terbium ion exhibits a fluorescence emission
maxima at ~ 545 nm through the energy transfer from the tryptophan residues from 7E15N or 7E15Q
that emit at 325 nm, where the fluorescence intensity increases. Buffer B demonstrates the NTA -Tb3+
complex formation spectra, and buffer A displays the NTA competing with Tb3+-ProCA1 variants complex
in solution during acquisition of each buffer samples. The intensity is decreased gradually as NTA is
titrated into the 7E15N-Tb3+ or 7E15Q-Tb3+ complex samples (Figure 4.8 e,f). During this process, NTA
competes out the Tb3+ from the ProCA1 variant’s binding pocket. At these decreased titration points,
there is less fluorescence energy exchange between the tryptophan residues and Tb3+ ion. Tb3+ free
concentration increases in solution and forms complex with the high NTA present in the sample A
buffer. As a result, there is decreased fluorescence intensity. Theoretically, the more NTA required
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competing out the Tb3+ from the ProCA1 variant’s binding pocket, then the stronger binding the ProCA1
variants demonstrate for binding to Tb3+. Both 7E15N and 7E15Q demonstrate a similar curve fit that
means that both mutations demonstrate a similar binding characteristic to Tb3+.

In following, 7E15E and ProCA1.affi.EGFR have a -5 charged binding pocket. Both variants
demonstrate similar binding characteristic to Tb3+ just as the -4 charged variants. The curve fit for these 5 charge variants are similar and demonstrates a lower binding affinity then the -4 charged variants.
Essentially, the -5 charged variants demonstrate a stronger binding affinity to Tb3+ based on the results
summarized in Table 4.2. The spectra for buffer A and buffer B demonstrate the gradual decrease in
fluorescence intensity during an increase in NTA concentration. Free Tb3+ concentration essentially
decreases as NTA-Tb3+ concentration increase, while 7E15E-Tb3+ and ProCA1.affi.EGFR-Tb3+ complex
decreases in concentration during the titration process.
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Figure 4.6 The determination of the free terbium concentration (μM) range between NTA-Tb3+ and ProCA1-Tb3+ buffer system
The competition assay consist of a) buffer system b: 50 mM HEPES, 150 mM KCl, 1 mM NTA and b) buffer system a: 50 mM HEPES, 150 mM
KCl, 1 mM NTA, 30 μM 7E15N-Tb3+ buffer system based on the fluorescence emission spectra overlay of the total terbium concentration (μM).
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Figure 4.7 Fluorescence emission for 7E15E, ProCA1.affi.EGFR, 7E15N, and 7E15Q in NTA-Tb3+ buffer system.
The measured fluorescence intensity of a) buffer B: 20 mM PIPES, 100 mM KCl, 500 μM Tb 3+, pH: 6.8, no protein presence as baseline
correction for 7E15E; buffer A: 20 mM PIPES, 500 μM Tb3+, pH: 6.8, with protein at 20 μM for 7E15E; alongside the curve fit for the -5 charged
binding pocket proteins: c) 7E15E and d) ProCA1.affi.EGFR, and the -4 binding pocket proteins: e) 7E15N and f) 7E15Q, based on the Hill
Equation.
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4.3.4 Fluo-5N competition assay
In the case of determining the binding affinity of ProCA1 variants toward Gd3+ ions, we devised a
competition assay that uses the Fluo-5N dye during titration of the protein in solution. Fluo-5N dye is
used as a probe that binds to Gd3+ at a low 10-12 M binding affinity for Gd3+. The protein is titrated in the
buffer system that contains the dye-Gd3+ complex. Fluo-5N dye gives emission maxima at ~515 nm and
the mean relative intensity is plotted as a function of the protein concentration (μM). The intensity
decreases gradually as the protein competes out Gd3+ from the dye-Gd3+ complex until saturation occurs
where there is unchanged fluorescence intensity. Only dissociation constant for 7E15Q and
ProCA1.affi1907 are demonstrated using the competition assay. Both variants differ in binding affinity
due to the values obtained for the Kd2 which is the dissociation constant of ProCA1 variant to Gd3+. The
apparent dissociation constant demonstrated by the curve fit for both 7E15Q (2.53 x 10 -5 M) and
ProCA1.affi.EGFR (1.81 x 10-5 M). The dissociation constant of 7E15Q-Gd3+ (9.61 x 10-11 M) and
ProCA1.affi.EGFR-Gd3+ (6.87 x 10-11 M) complex formation is calculated through Equation.
ProCA1.affi.EGFR shows a stronger binding affinity towards the Gd3+, which is an essential criterion as a
Gd3+ based contrast agent compared to the charged 7E15Q.

Since similar charged variants

demonstrated the same binding characteristics towards Tb3+, then it is presumed that charged variants
with a -5 binding pocket can demonstrate a similar characteristic for Gd3+ ion.
4.3.5 The summary of the metal-binding characteristics for all ProCA1 variants
The summary of these findings on the variants, charged and targeted, is compared in terms of
binding dissociation constant for both Tb3+ and Gd3+ (Table 4.1). The summarized binding study
establishes that the -5 and -4 charged variants demonstrate a strong binding affinity for both Tb3+ and
Gd3+. The specific site mutation to changing the net charge in the binding pocket assures that results
charge of the binding pocket does play an essential role in the metal-binding interaction based on the
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summarized results. It is safe to assume that the high charge-binding pocket is favorable for stronger
lanthanide ion binding. Furthermore, the ProCA1.affi.EGFR is the only targeted variant, which
demonstrates the lowest dissociation constant for both Tb3+ and Gd3+. Thus, the designed charged
variant with a -5 charge and design targeting capability is favorable for use as a contrast agent.
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Table 4.2 A summary of the dissociation constants of Tb3+ and Gd3+ toward the ProCA1 variants [22, 34].
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4.3.6 Relaxivity measurements for ProCA1 variants
The large-scale expression and the GST-tag purification of 7E15E, 7E15N, and 7E15Q from
Chapter 3 are treated with a chelator resin in a dialysis for overnight in oder to eliminate calcium and
other free ions present in the protein solution. Each protein sample are then collected and saturated
with the desired fixed GdCl3 concentration for relaxivity measurements. Specifically, 7E15E, 7E15N, and
7E15Q have one binding pocket designed to act as a chelating agent for Gd3+ ion. These measurements
are plotted as a function of the protein concentration. Theoretically, the observed phenomena is a sharp
increase in r1,r2 value then a gradual decrease following saturation of the r1,r2 values as the protein
concentration increases. 7E15E and 7E15Q demonstrate a similar curve pattern for r1,r2 and T1,T2 as a
function of the protein concentration. 7E15N displays a sharp increase in r1,r2 then an elevated increase
in these values soon follow with respect to the increase protein concentration (Figure 4.11 e) . In the
case of the T1,T2 values, 7E15N demonstrates a saturation with respect to the increase protein
concentration (Figure 4.11 b) . Essentially, the relaxation time values are inversely proportional to the
relaxation rate values. Thus, the compared curves for each ProCA1 charged variants should be a
reciprocal plot of one another assuming there are no experimental errors. Specifically, CD2.7E15E- Gd3+
complex decreases then saturates in T1,T2 values while the same sample complex increases then
saturates in r1,r2 values.
As discussed in Chapter 1, section 1.3.3 , the ProCA1 variants have one engineered binding
pocket with negatively charged amino acid side chains that form an ionic bond with Gd3+. Through the
formation of this complex in aqueous solution, in the presence of a magnetic field; relaxation time
values are measured using a minispec relaxometer with a 1.4 Telsa. The change in relaxivity values is
tested based on the one to one ratio of the protein to Gd3+ concentration as demonstrated in the bar
graph (Figure 4.12). Each value is labeled in correspondence to each protein variant. CD2.WT is used as a
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negative control. Since it has no mutations, the parent protein demonstrates the lowest relaxation rate
values as expected for ratio 1:1 with a higher relaxivity value. In terms of numbers, there are no
significant difference in the relaxivity values of the 1:1 ratio for all three charged variants. Overall,
7E15Q demonstrates the highest r1 and r2 values for 1: 1 ratio based on the values. In following, all the
relaxivity values measured based on the 1: 1 ratio fall under a similar range for all charged variants.
Thus, further analysis is needed for a concise conclusion to be achieved.
ProCA1.affi1907 targeted to EGFR and ProCA1.affi.HER2: 342 targeted to HER2/neu
demonstrate similar r1 and r2 values when comparing these two ProCA1.affibodies. It is expected that
these targeted variants display similar relaxivity values due to the fact that they both have the same
metal-binding pocket. The results (Figure 4.13) reassure that although the targeting peptide differs in
each of these two variants, there is an unchanged effect in the behavior of the binding pocket. In
addition, the linker that connects the grafted peptide and the scaffold ProCA1 enables the ProCA1
moiety that belongs to the variant to move freely without being hindered or restricted by the grafted
peptide on the c-terminal of ProCA1. Essentially, there is no particular difference in the relaxivity values
when the ratio of the protein to Gd3+ concentration is set as 1:1. Thus, an equal ratio of protein and free
gadolium is favorable for the ProCA1 variants during preparation of the complex ProCA1-Gd3+ for further
in vivo study. In addition, a concise dosage amount can be used for both targeted variants during animal
experiment.
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Figure 4.8 Relaxivity time (T1,2, ms) and rate (r1,2, mM-1s-1) for ProCA1 charged variants
The relaxivity values in terms of time a), b), c) (T 1,2, ms) and d), e), f) rate (r1,2, mM-1s-1) as a function of
the concentration of 7E15E, 7E15N and 7E15Q, with a fixed Gd3+ (50 μM, 80 μM, 50 μM) respectively.
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Figure 4.9 The average relaxivitys, r1,2 (mM-1s-1), of the charged ProCA1 variants with 1:1 ratio
concentration with Gd3+
The following conditions in terms of ratio are: ProCA1 variants (30 μM) and Gd3+ (30 μM) ----ratio 1:1.
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Figure 4.10 The averaged relaxivitys, r1,2 (mM-1s-1), of targeted ProCA1.affibody variants at varying
protein to metal ratio concentrations.
The following conditions in terms of ratio are: ProCA1.affi.HER2:342 (50 μM), ProCA1.affi.EGFR (50
μM), and Gd3+ (50 μM).
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4.4 Conclusion and Future work
The designed ProCA1 variants are analyzed for their structural beta sheet conformation and
functional characteristic as contrast agents through a series of biophysical applications. Such
instruments consist of far UV CD, intrinsic tryptophan fluorescence emission for the secondary and
tertiary conformation. In following, the functional characteristics as a lanthanide chelator are
demonstrated through two sets of fluorescence competition assays and the relaxivity measurements.
The results assure that after the purification method, the ProCA1 charged variant, 7E15Q holds its
secondary β-sheet conformation. Specifically, the structural analysis of 7E15Q purified from different
purification methods demonstrates a difference in minima and predicted helix and strand percentage
(Figure 4.5) for the far UV CD spectra. This phenomenon indicates that there may be some secondary
conformational change with proteins purified with the tag-less versus GST-fusion purification procedure
for 7E15Q. Further analysis is needed for the other ProCA1 variants in order to make a concise
conclusion about the effect each purification method has on the proteins secondary conformation. The
intrinsic tryptophan fluorescence emission spectra indicate that through different purification systems,
ProCA1 holds an intact hydrophobic core. Thus, the difference in purification system has no drastic
effect on the tertiary conformation of ProCA1. It can be presumed that other charged variants
demonstrate this similar stability in tertiary conformation because all demonstrate similar relaxivity
values. Therefore, there is no significant difference in the metal binding characteristics to Gd3+ when
measuring the relaxivity values between the three charged variants (7E15E, 7E15N, and 7E15Q).
Similarly, 7E15Q and ProCA1.affi.EGFR demonstrate dissociation constant towards Gd3+ at 10-11 M range.
It is presumed that the charged variants and targeted ProCA1.affi.EGFR variant demonstrate similar
binding characteristic towards Gd3+ based on the relaxivity and FLuo-5N-Gd3+ fluorescence
measurements. Interestingly, Tb3+ dissociation constant is similar for CD2.7E15Q and 7E15N that have a -
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4 binding pocket charge, while 7E15E and ProCA1.affi.EGFR demonstrate lowest Kd towards Tb3+. The
fluorescence emission spectra for FLuo-5N competition system need to be repeated since a large
standard error is demonstrated on the curve fit. Thus, the calculated Kapp and Kd2 are considered for reevaluation. In addition, further experiments for determining the other ProCA1 charged variants would
be executed as future work. This goal is set towards making a concise conclusion on the impact that the
different charges in the binding site has on the dissociation constant for Gd3+.
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5. PURIFICATION AND CHARACTERIZATION OF PROCA32 FROM A LARGE SCALE FERMENTATION
5.1 Introduction
As discussed in Chapter 1, Yang lab has developed a novel set of designed ProCAs with the goal
to proceed into the preclinical and clinical application. ProCA32 is a part of the 3rd generation of these
engineered contrast agents and holds two canonical EF hand-binding sites (contained in helices EF and
CD) and one additional EF-hand motif AB, which holds a mutation. The parent protein scaffold is
parvalbumin, which is a calcium binding protein. The natural function of this protein is to act as a
cytosolic Ca2+ buffer [68]. This protein differs with ProCA32 by one site mutation within the CD binding
pocket (S56D). Furthermore, an additional mutation (F103W) is made close to the CD binding pocket for
effective fluorescence emission analysis. The two binding sites on the parent protein and the advantage
of using this scaffold protein will effectively increase relaxation property. The characteristic of this
scaffold protein demonstrates sTable serum stability, has low toxicity and behaves as a ratiometric T1/T2
weighted contrast agent. The interaction with gadolinium and other metals are tested through a series
of biophysical applications in Dr. Shenghui Xue’s dissertation. His results suggest that this contrast agent
has a high metal selectivity with gadolinium. This protein scaffold holds a sTable conformation during
high temperature conditions. The advantages of this third generation of ProCA, specifically ProCA32
mutation, are directed for large-scale production. Specifically, the cultivation of this protein is run
though a GMP-like procedure that involves the fermentation process of a 15-liter culture volume. A
portion of the cell pellets generated from this over-expression is analyzed through relaxivity
measurements and NTA-Tb3+ buffer system. Initially, the fermented ProCA32 is purified by a set protocol
that efficiently utilizes streptomycin antibiotic that causes precipitation of unwanted contaminants such
as nucleotide fragments following cell lysis. The purpose of this Chapter is to successfully purify the
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fermented protein and analyze the metal-binding characteristic of this contrast agent through NTA-Tb3+
buffer system and relaxivity measurements.

Figure 5.1 The cartoon of the holo form rat-alpha parvalbumin with the indicated two EF-hand sites.
This image is generated using PyMOL software with the Pdb code: 1S3P (pink), and 1RWY (yellow) [30].
The EF-hand binding sites are indicated by the red arrows with Ca2+ represented as green sphere.
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5.2 Methods
5.2.1 Cloning
The cloning of ProCA32 variant is described according to the protocol in Dr. Shenghui Xue’s
dissertation [69].
5.2.2 Purification procedure of ProCA32
The following are the steps to the purification of the 180 g cell pellet collected from
fermentation: Thaw cell pellet (~ 180 g), Aliquot into 6 individual 50 mL falcon tubes, Add 40 mL PBS or
preferred buffer (i.e. 10 mM HEPES, pH: 7.0 or 10 mM Tris). Add 90 μL of PMSF (100 mM stock
concentration) and benzonase nuclease (1 μL). Suspended cell pellet in this lysis buffer by vortex or
stirring prior to sonication. Once a homogenous mixture was achieved– sonication (5X) each sample for
30 sec. with 5 min interval time--- obtaining a lysis solution. The extraction of the protein was done by
lysis solution with cell disruptor for three times (3X). Centrifugation was set at a high speed (17,000 rpm)
then boiled the supernatant (SN) in a water bath for ten minutes. Centrifuged the solution along with
the white precipitant formed at low speed (6,000 rpm) using the bench- top centrifuge (MR 1812) for
ten minutes. Kept the supernatant and discarded the pellet, then added 3 % streptomycin to precipitate
DNA and nucleic acid fragments. The solutions with streptomycin were placed at 4 °C for overnight.
Centrifuged solution at 6, 000 rpm for ten minutes. Heated the sample by placing the supernatant in a
water bath for another ten minutes, and centrifuged again for an additional ten minutes. Collected
supernatant and transferred into dialysis bag and placed in 10 mM HEPES buffer overnight (change
buffer twice). This procedure was developed and repeated as described in Dr. Shenghui Xue’s
dissertation [69].
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5.3 Results and Discussion
5.3.1 The purification of ProCA32 from expression through fermentation
As mentioned earlier, ProCA32 is fermented at a large 15 L volume but the purification is based
on the 2 Liter aliquot of the cell pellets. The aliquot pellet holds approximately 180 g of overexpressed
protein. One fraction of these cell pellets is broken down through a series of steps for the purification. In
Figure 5.1, the 15 % SDS-PAGE summarizes each sample of the soluble and insoluble form of each
samples related to the series of steps in the purification protocol. The expression is fairly high as
indicated by the band intensity. The initial step in purifying the protein is the separation of the soluble
and insoluble form through centrifugation. ProCA32 has a relatively high ratio in the supernatant versus
inclusion body, which means that the larger ratio of the protein is present in the supernatant samples as
demonstrated in lane 1, 3, 5-10. All lanes containing the soluble form of the protein indicate an intense
band. In the second and proceeding steps for the purification of ProCA32, heating and treatment with
antibiotic called streptomycin is key for removal of unwanted proteins and nucleotide fragments.
ProCA32 is a uniquely devised protein that withstands a sTable structural conformation in the presence
of high temperature. Thus, boiling the sample is an efficient and practical manner for removal of
unwanted and unsTable protein. Further isolation with the nucleotide and other impurities are achieved
through FPLC- anion exchange Q column with a salt gradient program. The higher the percent salt
concentration increases, the lower affinity the ProCA32 has with binding to the Q column and through
competition with the high ion present in the buffer system, the protein of interest is eluted out by 2 mL
fractions.
Initially, the FPLC system runs the set program that initiates the injection of the protein sample.
The milli-absorbance units (mAU) of the peak fractions are detected by the UV- lamp at 280 nm, once
the sample passes through the instrument system. These peaks are viewed in the FPLC program as a
function of the buffer volume (mL). A 10 mL injection volume is set for each run to avoid oversaturation
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of the 5 mL Q-column, mAU readout, and increase resolution on the FPLC. An overall set of 37 runs is
achieved for ProCA32 as a result. The initial FPLC run demonstrates 5 peaks. Each fragment is analyzed
for the detection of ProCA32 through 15 % SDS-PAGE results (Figure 5.5). Peak two and three are the
main regions in which the protein of interest is present between the 35 % to 75 % salt concentration.
The DNA gel demonstrates the successful isolation of nucleotide fragments post FPLC in peak five. Peak
two and three are kept separated until all the fraction runs are gathered.
The UV-Vis absorbance spectra for the fractions combinations (15-17, 19-21, 23-31) indicate the
presence of ProCA32 based on the 280 nm maxima and the distinct shoulder (this characteristic has
been also observed in Dr. Shenghui Xue’s study) at ~295 nm (Figure 5.3). The 18th FPLC run has a higher
resolution as demonstrated by the separated middle peak two and three. As we go through each
consecutive FPLC run, the model chromatograph indicates four distinct peaks where each are eluted out
based on the salt gradient. It’s presumed that nucleotide contamination is present in the highest salt
concentration based on the agarose gel demonstrating the high concentration of DNA for fractions 42 to
48 (Figure 5.5). Thus; peak four contains nucleotide contamination that has been successfully isolated
from the protein sample. ProCA32 sample (400 mL) from dialysis took approximately nine days to isolate
by FPLC.
The collection of SDS-PAGE demonstrates the samples for each combined fractions throughout
all the 37 FPLC runs. All the highlighted fragment combinations indicate that a significant concentration
of ProCA32 is present after running the FPLC. The common peak fractions for ProCA32 mainly fall in the
fragment number 17 to 31 as indicated by the protein bands at the ~ 12 KDa mark. Each samples are run
as an effective way of screen which combine fractions contains the clear protein band at the ~ 12 KDa
mark. All combined fragment samples are then individual scanned through a UV-Vis spectrophotometer
for comparing the level of nucleotide contaminants possibly present after FPLC isolation. The 260 nm to
280 nm absorbance maxima for each combined fractions and the corresponding FPLC run number are
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quantified and compared based on a ratio in Figure 5.5. The gel samples demonstrated in Figure 5.4
correlate to the same samples with the compared absorbance ratio from Figure 5.5. The identification of
the level of nucleotide contamination through UV-Vis absorbance is used as a way to quantify the
approximate concentration level of nucleotide, other than using the DNA agarose gel. Essentially, all the
combined fractions that initially indicated the presence of ProCA32 are further analyzed by 260 nm/ 280
nm absorbance ratios prior to ultrafiltration. The numerator represents the absorbance maxima at 260
nm, representing the nucleotides, while the denominator of the ratio represents the absorbance
maxima at 280 nm for ProCA32. Since all sets of the combined fractions demonstrate a higher ratio to
0.50, the set ratio range to be analyzed is between 0.50 and 1.50. In following, the individual set of
combined fractions is separated into two categories based on the ratio level that is lowest or highest to
1.50. Overall, ten of the twenty-nine combined fragment sets indicated ratios within the specified range.
These samples are combined and concentrated under inert gas by ultrafiltration to a final 20 mL volume.
The overall yield obtained from after concentrating the initial 400 mL volume of dialysis ProCA32 is 768
mg per ~ 2L (Figure 5.6). Thus, theoretically, 384 mg/L is effectively isolated and purified within a month
span. Furthermore, the purified samples are analyzed for metal-binding characteristic.
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Figure 5.2 The purification gel of ProCA32 based on the purification method from Shenghui Xue’s
dissertation.
The 15% SDS-PAGE contains samples taken throughout the purification process of the fermented
ProCA32. Each lane are numbered and are represented as follow: 1) Supernatant after cell disruption,
2) inclusion body after cell disruption, 3) supernatant after heating for 10 minutes, 4) inclusion body
after heating for 10 minutes, 5) supernatant after adding streptomycin from sample before overnight
and 6) after overnight, 7) supernatant after cell disruption for the 2nd suspended pellets, 8
supernatant after adding streptomycin for the sample after overnight, 9) supernatant after dialysis
twice overnight for 1st and 10) 2nd pellet suspension.
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Figure 5.3 The isolated DNA/nucleotide contamination is successful as indicated by the agarose gel
Each specified fractions in the red box indicate the labeled samples 1 to 5. The sample fraction labeled in peak 5 demonstrates a strong
DNA/nucleotide contaminant that is eluted last at the highest salt gradient percentage ( ~ > 70 %).
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Figure 5.4 The UV-Vis spectra indicate successful isolation of the protein of interest within the corresponding peak fractions.
Run #18 is displayed above by the FPLC anion Q- column exchanger. The injection volume total into the Q Hitrap column is 10 mL of the
ProCA32 solution. ProCA32 is mainly present in fractions 15 to 31, as the small shoulder (at ~ 295 nm) exhibits possible protein in solution.
The two-disctinct peaks 2 and 3 represent the holo and apo form of ProCA32, respectively. Fractions 32 to 36 do not exhibit this
phenomenon.
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Figure 5.5 The 15% SDS-PAGE of the isolated ProCA32 to the other contaminants.
The nucleotide fragments demonstrated in lane 5 of a) the agarose gel. In following, the 15 % SDSPAGE indicates the combined fragment sets in correspondence to FPLC b) run # 1-4, c) run # 5-8, d) run
# 8-11, e) run # 12-16, f) run # 16-19. Each highlighted red combined fractions indicate the presence of
ProCA32 at ~12 KDa.
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Figure 5.6 Comparing the absorbance ratio between each fraction range for ProCA32.
The A260 nm/ A280 nm ratio is higher when the presence of nucleic acid is at a higher maxima value at 260 nm compared to the maxima
absorbance value at 280 nm for ProCA32. The diluted samples are indicated with the dilution factor as (800 μL of total Protein and buffer to
50 μL) for Absorbance maximum at 280 nm. The highlighted red fragment sets represent the specified ratio range between 0.50 and 1.50 for
the lowest possible amount of DNA/ProCA32 concentration in terms of absorbance maxima values.
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Figure 5.7 The final yield corresponding to ~ 180 g from the 2 liter aliquot pellet of fermented
ProCA32.
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5.3.2 The study on the metal-binding capability of ProCA32
5.3.2.1 NTA-Tb3+ buffer system of ProCA32
Two sets of biophysical techniques are used on the concentrated ProCA32 sample after the
purification process described in Section 5.3.1. The metal binding capability of the site mutation in the
EF hand site and the other binding site of ProCA32 are characterized based on the dissociation constant
through an NTA-Tb3+ buffer system. It is essential to characterize the Tb3+ binding capability of the
fermented ProCA32 and compare the findings to previous work established by Dr. Shenghui Xue. The
protein stability is demonstrated by the low dissociation constant at 10-13 M range. Specifically, ProCA32
sample demonstrates dissociation constant (5.82 x 10-13 M) much weaker than the previous (1.21 x 10-23
M) determined results Dr. Shenghui Xue. There maybe two factors to consider for understanding the
difference in dissociation constants. One plausible reason is that there are different buffer systems used,
the previous results used 50 mM HEPES while the current results demonstrated (Figure 5.7) utilized a 20
mM PIPES buffer. The second reason is the difference in Tb3+ and NTA concentration between the
current result that uses 500 μM and the previously determined Kd for ProCA32 used 1 mM for both NTA
and Tb3+. In a sense, the difference in NTA and Tb concentration is most reasonable since theoretically
the determined Kd is approximately half the Kd value of that determined in Dr. Shenghui Xue ‘s
dissertation. In addition, the protein concentration used is 20 μM compared to the 30 μM concentration
of ProCA32 used in the previous studies. Thus, the dissociation constant observed is plausible for
determining the binding capability of the two binding pockets to Tb3+.
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Figure 5.8 Fluorescence emission for 7E15Q and ProCA1.affi.EGFR in Fluo-5N competition assay
The fluorescence emission spectra overlay for buffer system: 20 mM PIPES, 100 mM KCl, pH: 6.8, a)
with 7E15Q or b) ProCA1.affi.EGFR; alongside the curve fit with the normalized relative fluorescence
intensity as a function of [7E15Q], μM or d) [ProCA1.affi1907], μM. The determined K app represents
the apparent dissociation constant of FLuo5N-----Gd3+-ProCA1 variant, while the Kd2 represents the
actual dissociation constant for ProCA1-Gd3+ complex formation.
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Figure 5.9 The fluorescence Intensity of NTA-Tb3+ buffer system with ProCA32.
The measured fluorescence intensity of a) buffer B: 20 mM PIPES, 100 mM KCl, 500 μM Tb 3+, pH: 6.8, no protein presence as baseline
correction for ProCA32; b) buffer A: 20 mM PIPES, 500 μM Tb3+, pH: 6.8, with protein at 20 μM for ProCA32; alongside the curve fit based on
the Hill plot.
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5.3.2.2 Relaxivity measurements of ProCA32
Relaxivity measurements are gathered as a way to identify the metal binding interaction in the
presence of a magnetic field for ProCA32.

There are two sets of relaxivity measurements. One

experiment demonstrates the high relaxivity values at varying ProCA32 to Gd3+ concentration ratio,
while the other experiment demonstrates the saturation curve as relaxivity is measured versus the
increased ProCA32 concentration (μM range). Figure 5.8 shows the difference in relaxivity values for
each set of purified ProCA32 samples. Sample one differs in the expression system used compared to
sample two and three. Sample two differs in the purification system used compared to sample one and
three. Basically, there is a significant difference in relaxivity values for each of these samples, which
indicates that both the expression and purification systems have an impact on the metal binding
characteristic of ProCA32. Sample one has a highest relaxivity values for 1:2 ratio compared to the 1:1
ratio. Similarly, sample two and sample three also have a higher relaxivity value for 1:2 ratio rather than
the 1:1 ratio. These results coincide with the fact that two binding pockets are involved, thus the Gd 3+
concentration needs to be increased compared to the protein concentration. Furthermore these results
correlate with previous findings that ProCA32 variant demonstrate higher relaxivity values with a higher
Gd3+ to protein concentration. Theoretically, only one binding pocket is occupied by the Gd3+ ion in the
1:1 ratio while at increased Gd3+ to ProCA32 concentration, there is an increase chance of both binding
sites to be bound to Gd3+ in solution. Essentially, the relaxivity depends on the per Gd3+ ion present in
solution for ProCA32. Sample one demonstrates the highest relaxivity values as compared to sample
two and sample three for both ratios.
To proceed, the second set of relaxivity measurements is demonstrated in Figure 5.9. The
relaxivity time and the relaxivity are plotted and compared side to side as a function of the increased
ProCA32 concentration. Theoretically, as the protein concentration increases, the relaxivity increases up
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to the 1:1 ratio then gradually reaches a saturation mark (Figure 5.9b). The relaxivity times (T1,2 ,ms) are
inversely proportional to the rate values. A sharp decrease in the time values is observed then an
increase and saturation in those values follows, while increasing the protein concentration. The same
stock protein sample is analyzed (Figure 5.9) but it demonstrates a lower relaxivity value during the 1:2
ratio. The change in the relaxivity values for ProCA32 sample may be caused by the sample preparation
error while using different GdCl3 stock concentration. This reasoning is plausible since the relaxivity
values summarized in Table 5.1 are similar to the 1:1 ratio in Figure 5.8 for sample. Thus, the relaxivity
values of ProCA32 are much higher with two occupied Gd3+ binding sites than that of one occupied Gd3+
binding site.
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Figure 5.10 The different relaxivity values for ProCA32 in different expression/purification procedure.
A comparison between the relaxivity values of the different purification methods for ProCA32 demonstrates a higher relaxivity value for the
60 X 1 Liter flask/streptomycin sample compared to both fermentation samples. The conditions involved are: ratio 1:2 --- 50 μM ProCA32 and
100 μM Gd3+, ratio 1:1 --- 100 μM ProCA32 and 100 μM Gd3+.
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Figure 5.11 The saturated a) T1,T2 (ms) values and r1,r2 (mM-1s-1) values for the fermented ProCA32 with a fixed Gd3+ (50 μM).
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Table 5.1 The summarized relaxivity values and Kd value for the metal binding study for ProCA32.

157

5.4 Conclusion and Future work
There is successful purification of ProCA32 from a large cell amount (~ 180 g = 30 X 1L when
considering that 6 X 1L = ~36 g). The 400 mL total of ProCA32 is obtained after dialysis to diffuse out all
unwanted streptomycin and nucleic acid derivatives. Total volume achieved is consistent when
considering the overall volume in which the protocol involves (2 x (40 mL x 6 tubes) = ~ 480 mL. The time
consuming portion of the purification is isolating the unwanted protein and nucleotide by use of FPLC
system. As future work, isolation technique using ion exchange column with a salt gradient is followed
for further purification procedure. Agarose gel and UV-Vis absorption are some techniques applied for
successful detection of nucleotide derivatives and obtain overall concentration of the sample labeled
three. The expression and purification systems do play a major part in the proteins metal binding
characteristic as supported by the difference in relaxivity values. The Kd value for Tb3+ binding to
ProCA32 (5.82 x 10-13 M), r2 (27 0.54 mM-1s-1), and r1 (20.6 0.20 mM-1s-1) demonstrate the metal-binding
interaction between the two binding sites and the lanthanide metals (Gd3+ and Tb3+).
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6. SIGNIFICANCE AND MAJOR FINDINGS OF THIS THESIS
Overall, Yang lab has developed a novel class of protein-based contrast agents (ProCAs) that
effectively increase the relaxation rate. Our goal is to fulfill all the necessary criteria involved in
achieving the ideal relaxation rate in order to enhance the image. These ProCAs are administered to
mice with various diseases models at a milligram amount for in vivo study. To promote the clinical
application of ProCAs, the production of the agents with optimized biophysical characteristics and
biological function is essential. In order to achieve this final goal of clinical application, there are six main
questions that have been addressed in this thesis to determine a reliable and repeaTable production
protocol for rat derived ProCAs.
A. The Production of ProCAs:
1. What are the optimal expression conditions for the cultivation of each ProCA1 variants in
the tag-less system?
2. What are the optimal conditions for the expression system of GST-tagged ProCA1 variants
and whether each ProCA1 variant demonstrates a different expression pattern?
3.

Whether the total yield (mg/L) of the denaturing-refolding purification method for the tagless ProCA1s and GST-tagged ProCA1s is comparable or not?

4. How much impact of the lysis buffer condition has on ProCA1 variants’ yield of the GST-tag
purification?
B. The structural conformation and metal-binding capability of ProCAs:
5. What is the relationship of metal binding affinity and proton relaxation values with
structural conformation of each ProCA1 variant?
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6. Does the ProCA32 mutant retain structural stability after a large-scale fermentation? What
is the overall effect of the purification and cultivation methods on the proton relaxation
property?

I.

In Chapter 2, we focused on studying the influence of different E. Coli host cell strain on the

expression yield of each ProCA1 charged variants including 7E15E, 7E15N, and 7E15Q. We also studied
the correlation of the purification yield with the protein expression level.
The major findings for the tag-less expression and purification results indicate that all ProCA1
variants (i.e. 7E15E, 7E15N, 7E15Q) are successfully denatured then refolded with an increased yield ( ≥
12 mg/L) from cultured E.Coli cell strains (BL21 (DE3) and Tuner). ProCA1 variants have highest
expression in Tuner cell strain. Rosetta-gami (DE3) pLysS and BL21 (DE3) pLysS cell strains gave low to no
expression of ProCA1 variants at the set IPTG concentration (20 mM) and post induction temperature
(25 °C, o/n). Tuner cell strain promotes solubility of the extracted ProCA1 variants during cell lyses, and a
future small-scale reproduction confirms reassure this finding based on the set IPTG and post induction
temperature.

II.

In Chapter 3, we focused on the influence that different E. Coli host cell strains, post induction

temperatures, and /or inducer concentrations have on the expression yield of each ProCA1 charged
variants, 7E15E, 7E15N, and 7E15Q. In addition, we raised the question whether or not the specific
modifications in the lysis buffer will affect the purification yield of cleaved GST-tagged ProCA1
variants.
The major findings for GST-tag expression results suggest that the method at low temp with a
longer cultivation time for the three charged variant proteins’ (7E15E, 7E15N, 7E15Q) expression level is
most favorable while a shorter cultivation time at a high temperature is suiTable for the targeted
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ProCA1 variants (ProCA1.affi342 & ProCA1.affi1907). These results can be further tested to confirm that
the grafted peptide may have some indirect influence on the expression behavior of the targeted
ProCA1 variants as compared to the original ProCA1 charged variants. Two different purification
systems, tag-less (Chapter 2) versus GST-tag (Chapter 3) were analyzed for the same ProCA1 variants
and the yields were compared. The final result demonstrated that tag-less purification through the
denatured-refolding process proves most beneficial in terms of the higher protein yield output in mg/L.
In the GST-tag purification, refolding, and modifying the current lysate buffer conditions in A into
lysate buffer B is essential for obtaining a high yield as demonstrated by 7E15E (9 mg/L) and 7E15N (4
mg/L). There is some discrepancy to the data because 7E15Q, ProCA1.affi342, and ProCA1.affi1907
demonstrate a highest yield in the respective lysate buffer conditions, A (10 mg/L), C (5 mg/L), and D (7
mg/L). Essentially, the bottle neck for the expression and purification procedures needs to be examined
further for the rat derived ProCAs so that these results can be transitioned and compared with the
currently expressed and purified human derived ProCAs from results of other current lab researchers.

III.

In Chapters 4 and 5, we analyzed the secondary structural conformation, the metal binding

study, and relaxation property of both ProCA1 charged and targeted variants, and ProCA32.
Circular dichroism, fluorescence titration, and relaxivity measurement are major applications that
are applied for a varied compilation of results on the structural conformation and metal binding
behavior of the purified ProCA1 variant samples (Chapter 4). These biophysical applications require a
set amount of protein stock concentration as listed in Table 2.1. In the metal binding study, the
dissociation constant to Tb3+ falls in the 10-12 - 10-13 M for -5 charged binding pocket and 10-12M for -4
charged binding pocket while the dissociation constant to Gd3+ is similar for both -4 and -5, due to large
error bar. The relaxivity measurements at 1.41 Tesla are consistent with previously collected data, and
are to be repeated to determine reproducibility of data.
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The significance of this thesis is directed towards the production phase of these novel engineered
protein-based contrast agents (ProCAs) for MRI application. One major point is to seek optimal
conditions through changing the parameters during expression and purification methods to obtain a
high yield, high purity, and sTable functioning ProCA chelator through an effective, low cost procedure.
It is evident that the long term goal is to set a standard optimal expression and purification method that
is favorable for current good manufacturing practice (cGMP)-like, able to transition into an industrial
large scale method for application in vivo, specifically for further pre-clinical applications with large
animal models (i.e. rats, dogs, monkeys).
The clinical application is to administer this novel designed protein-based contrast agent (ProCA)
for MRI. The reasons for aiming our focus at developing MRI based agents are that 1) MRI is noninvasive, 2) has no depth limitation, and 3) provides high spatial and 3 dimensional view of soft tissues in
the body. These characteristics set this modality apart from other widely used imaging tools used in
medical research. An image enhancement is achieved based on the addition of a substance known as a
contrast agent. However, the major barrier to extend MRI for molecular imaging of disease for early
detection and prognosis is due to limitations associated to various clinical approved contrast agents such
as Gd3+-DTPA with low relaxivity and undesired pharmacokinetics and the high injection dosage amount
(0.10 mmol/kg). Our designed MRI contrast agents with high relaxivity and biomarker targeting
capability are expected to overcome the urgent medical needs and extend the application of MRI to
early detection of various human diseases, monitor treatment effect and facilitate development of new
drug and treatment strategy.
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